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 The development of fully automated and high-throughput systems for proteomics is 
now in demand because of the need to generate new protein-based disease biomarkers. 
Unfortunately, it is difficult to identify protein biomarkers that are low abundant when in the 
presence of highly abundant proteins, especially in complex biological samples like serum, 
cell lysates, and other biological fluids. Membrane proteins, which are in many cases of low 
abundance compared to cytosolic proteins, have various functions and can provide insight into 
the state of disease and serve as targets for new drugs making them attractive biomarker 
candidates. Traditionally, proteins are identified through the use of gel electrophoretic 
techniques and two-dimensional protein profile patterns have been used as potential 
diagnostic tools for biomarker discovery and the profiles from protein content of body fluids 
or cells are available in databases.  
However, gel electrophoretic methods are not always suitable for particular protein 
samples. Microfluidics offers the potential as a fully automated platform for the efficient 
analysis of complex samples, such as membrane proteins and do so with performance metrics 
that exceed their bench top counterparts. In recent years, there have been various applications 
and improvements to microfluidics and their use for proteomic analysis reported in the 
literature. In addition, microfluidics offers the potential of a disposable, low cost, and easily 
fabricated method to perform analysis on complex samples. In this work through the use of 
microfluidic devices, we demonstrate the ability to effectively extract and purify biotinylated 
cell surface membrane proteins from the cell lysate of MCF-7 human breast carcinoma. In 
addition, we also attempt to separate membrane proteins from MCF-7 cells. 
 xxii 
Our on-chip assay (µ-solid-phase extraction, µSPE) allows us to extract membrane 
proteins and rid the sample of contaminating cytosolic proteins (purification) in order to do 
further analysis on the membrane proteins. We also attempted to separate a complex 
biological sample using a microchip that is suitable for multidimensional techniques that 
employed sodium dodecyl sulfate micro-capillary gel electrophoresis (SDS µ-CGE) in the 1
st
 
dimension and micro-micellar electrokinetic capillary chromatography (µ-MEKC) in the 2
nd
 
dimension. Proteins were detected by laser-induced fluorescence following their labeling with 
dyes. Because our overall goal of this work is the development of a completely integrated 
system for the analysis of complex protein samples, we also discuss the integration of the 
extraction module with the separation module along with fabrication steps toward the 
integration of modules for the digestion of proteins on chip and interfacing the device with 
MALDI-MS.
 1 
1 Microfluidics for the Analysis of Integral Membrane Proteins: A Top-down 
Approach 
 
1.1   The Study of Proteins  
1.1.1 The Proteome and Proteomics  
The field of proteomics is focused on the determination of structures, expressions, 
interactions, and functions, which includes activities, roles and localizations of the proteome - 
a catalogue of the proteins in a specific organism coded by the genome. The original 
definition of the proteome views it as the protein complement of the genome, thereby not 
accounting for the numerous post-translational modifications and the varying state of 
proteins.
1,2
 Proteomics involves a comprehensive analysis, including the determination of 
structure, modifications, expression levels, localization and protein-protein interactions, 
within a given organism, cell, biological fluid, or tissue. Schramm et al.
3
, reported that 
proteomics involves the functional analysis of the full set of proteins by high-throughput 
technologies in a given system. This definition suggests that proteomics goes beyond 
identification and that protein analysis requires advanced technologies, such as high-
throughput processing techniques. Proteomics attempts to tackle three main areas of interest: 
(1) protein expression; (2) protein structure; and (3) protein function.
4
 
1.1.2 Challenges in Proteomics 
Various populations of proteins perform the higher biological functions in the cellular 
network making proteomics an attractive tool for research and scientists alike.
5
 In cancer 
research, particularly in identifying biomarkers for new drugs and drug discovery, proteomics 
is vital because proteins have been selected for investigation as biomarkers because of their 
past performance as biomarkers for other disease states or other cancers or because of their 
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function or family relationships.
6
 Throughout the past twenty years, there has been a growing 
interest in approaches toward discovering new biomarkers that may allow early diagnosis, 
prognosis, classification of disease subtypes, prediction of treatment response, and 
identification of potential targets for drug therapy. For most of these applications, a single 
marker is likely insufficient for stratification, and a panel of markers, i.e. molecular profiles or 
biosignatures can be more useful. Such biomarker profiles can be identified at different 
molecular levels, such as DNA, RNA, microRNA, and protein. A significant portion of the 
biomarker discovery efforts using -omics approaches has been in the area of cancer, and 
several markers are already in routine clinical practice, such as K-Ras mutation and HER-2 
amplification. A particular area of interest is the cell surface proteome due to its ease of 
accessibility and the possibility to serve as an ideal target for novel protein drugs. Most 
acknowledge the importance of proteomics as procuring extensive information required for 
the entire supplement of proteins comprising the proteome.  
Traditionally, proteomic analyses of complex protein samples involve the resolution of 
proteins using two-dimensional (2D) gel electrophoresis that includes isoelectric focusing 
(IEF) coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and followed by the identification of resolved proteins by mass spectrometry.
7,8
 The idea of 
building protein databases was proposed using subtractive pattern analysis of these gels.
9-11
 
Over time, with the advances in analytical protein technologies and advancements in mass 
spectrometry, it became possible for many proteins to be resolved by 2D-PAGE. However, 
the disadvantages of 2D-PAGE include a large amount of sample handling, a limited dynamic 
range, and difficulties resolving low abundance proteins
12-14
 with extreme pI and molecular 
weights,
15,16
 and hydrophobic proteins such as membrane proteins.
7
 The solubility of 
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hydrophobic proteins (membrane proteins) is problematic due to incompatibility with the IEF 
buffers, and if the proteins are solubilized, they are prone to precipitation at their isoelectric 
point (pI). To alleviate the issue of solubility with IEF buffers, many investigators have used 
1D gel coupled with mass spectrometry for identification of the proteins.
17-19
 Yet, the 
limitation of this approach is the increased protein complexity in each 1D gel band. 
Shotgun methods provide a powerful alternative to 2D gels. Shotgun proteomics is 
analogous to shotgun sequencing where DNA is broken into small fragments; these fragments 
are sequenced, and recombined in silico to determine the DNA sequence of an organism. In a 
general shotgun proteomic pipeline, a mixture of proteins is digested into peptides (using 
proteases such as trypsin), the peptides are loaded onto at least a two-dimensional 
chromatography based separation system, peptides are eluted into a tandem mass 
spectrometer in an automated fashion, and the resulting tandem mass spectrometry data is 
analyzed by powerful computational systems. Proteins are first digested with proteases into a 
more complex peptide mixture that is then analyzed directly by LC/MS and protein 
identifications are determined by database searching software.  
 This general approach is rapid and readily automated, but requires significant 
computing resources for data analysis. Moreover, as with gel-based methods, the solubility of 
membrane proteins is also a major challenge for non-gel shotgun approaches. Large scale 
shotgun proteomics effectively began with the introduction of multidimensional protein 
identification technology (MudPIT) in which a microcapillary column is packed with reversed 
phase (RP) and strong cation exchange (SCX) packing material, loaded with a complex 
peptide mixture and placed in line between an HPLC and a tandem mass spectrometry 
system.
20-22
 In addition to 2D gel and shotgun proteomic techniques, industrial-scale (liters) 
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approaches have also been reported for sample pooling of smaller proteins < 40,000 Da and 
fragments of large proteins. Using over 12,000 plasma fractions, Rose et al.
23
 reported 
thousands of peptide identifications, which permitted the identification of 502 different 
proteins and polypeptides from a single pool.  
Given the cost (liter-scale amounts of protein) and labor intensiveness (2D gel 
techniques) of such methods, they are clearly not applicable to routine clinical tests and are of 
marginal use in confirming candidate biomarkers where thousands of individual samples must 
be analyzed separately to placate statistical criteria for diagnostic specificity and sensitivity. 
Regrettably, proteomics is still burdened with numerous challenges that hinder its goals. 
These challenges can be categorized as; (a) the sample type; (b) limitations of bench-top 
approaches; and (c) analysis of data. 
1.1.3 Complexity of Protein Sample  





 Proteins sizes can range from a few amino acids to several thousands making 
them a very diverse and distinct class of molecules. They possess wide pI ranges and can be 
hydrophilic or extremely hydrophobic to the point where they are almost irretrievable from 
aqueous media.
26
 For example, proteins associated with the cell membrane contain 
hydrophobic domains that make them particularly difficult to analyze using traditional 
methods such as isoelectric focusing (IEF). Because of their hydrophobic and basic (as in 
charge) nature, and frequently large size, their isolation is not easy.  
A primary difficulty encountered in the study of membrane proteins is that of 
obtaining the protein of interest. Membrane proteins are usually present at low levels in 
biological membranes, and it is rare that a single protein species is a major peptidic 
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constituent of the membrane.
27
 In addition most membrane proteins cannot be readily 
obtained in sufficient amounts from their native environments and thus attempts are made to 
overexpress them. A second difficulty is that membrane proteins are naturally embedded in a 
lipid bilayer, which in even the simplest organism is a complex, heterogeneous and dynamic 
environment. This limits (but does not exclude) the use of many standard biophysical 
techniques to determine structure and function such as X-ray crystallography, circular 
dichroism, NMR, ligand-binding studies, classical kinetic characterization, the identification 
of structure–function relationships and also restricts applications since they require the protein 
to be extracted from its native membrane and studied in a detergent or lipid environment in 
vitro.
27
 This necessity leads to difficulties in sample preparation and spectral contributions 
from lipids. Finally, membrane proteins are not generally soluble in aqueous media.  
The need for membrane proteins to inhabit surroundings that satisfy their 
hydrophobicity therefore requires special synthetic systems for in vitro work. Unfortunately, 
reconstituting purified proteins into such systems has proven to be very difficult. Despite the 
problems of working with membrane proteins, they remain an important area for study due to 
their role in the control of fundamental biochemical processes and their importance as 





 and chemical treatment
30
 typically result in high purity 
but are often cumbersome and protein yields are poor. The dynamic range (i.e. abundance, 
size, function) of proteins within a single cell can span close to six orders of magnitude.
31
 It 
has been estimated that between 100,000 to 250,000 proteins are encoded by roughly 25,000 
human genes through post-translational modifications and differential splicing, which can 




1.1.4 Limitations of Bench-top Approaches for Proteomic Analyses 
 Proteomics attempts to simultaneously determine the identities, functions, and 
quantities of proteins.
34
 The need for large sample volumes, poor performance and labor-
intensive demands are all challenges associated with available bench-top techniques used in 
proteomics.  
For example, IEF-PAGE coupled with SDS-PAGE is a common strategy used to form 




 and a limit-of-detection 
(LOD) ~10
-6
 M. This technique can routinely resolve >2,000 spots per gel, which is well 
below the amount of proteins present in a proteomic sample. Moreover, it requires well-
trained personnel, has limited automation potential, and can be time consuming.
35
 Mass 
spectrometry (MS), on the other hand, provides better LOD (~10
-15
 mole for peptides) and 
high specificity, however, 2D-PAGE cannot be coupled on-line with MS to achieve a fast 
multidimensional protein separation and identification.
36
 As a result, multi-dimensional liquid 
phase-based separation methods using different electrophoretic and chromatographic 
techniques have been greatly developed as complementary methodologies because they can 
be coupled on-line with mass spectrometers for protein identification. The feasibility of multi-
modular combinations of high-performance liquid chromatography (HPLC), isoelectric 
focusing (IEF), chromatofocusing (CF), capillary electrophoresis (CE) as well as 
combinations of different HPLC modes provides numerous options for the separation of 
protein complexes and peptides.
37
  Ion-exchange chromatography (IEX) together with 
reversed-phase (RP) liquid chromatography (RPLC) is one example of orthogonal 2D-LC 
analysis.
38
 The total peak capacity in this 2D separation can be greater than 5000 and high-
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sensitivity peptide identification may therefore be achieved because of increased resolution 
and the resultant decrease in peptide overlap.
39
  
Among various kinds of 2D-LC techniques, the combination of strong cation 
exchange (SCX) mode separation in the first dimension and RP separation in the second 
dimension has become a dominant separation technology. As a classical proteome research 
strategy, this SCX–RPLC approach provides a large amount of biological information as a 
complement to traditional 2D-PAGE approach. Fujij et al.
40
 described an on-line SCX–RPLC 
workflow involving stepwise salt elution using ammonium formate that was employed for 
SCX separations and the resulting fractions were subjected to RPLC-MS analysis after 
concentration and desalting. Vitali and co-workers
41
 also employed SCX–RPLC with tandem 
MS (MS/MS) strategy to identify proteins from Bifidobacterium infantis. Digested proteins 
were first separated through a SCX column and the fractions were collected every minute. 
After drying and resuspension, protein fractions were further separated and identified through 
a homemade RPLC coupling with a quadrupole time-of-flight (Q-TOF) mass spectrometer. 
However, there is no amplification technique in proteomics similar to PCR in 
genomics and therefore, proteins must be analyzed in their native concentrations. Also, 
because of the inability to amplify protein targets using techniques employed in genomics, 
proteome analysis can be much more challenging. This can be compounded by the high 
complexity of proteome samples. No single chromatographic or electrophoretic procedure to-
date possesses the peak capacity required to resolve a complex mixture, such as that found in 




1.1.5 Complications of Protein Data Analysis  
Measurable parameters in proteomics are large in number, and require many 
biological and methodological replicates, which may not be so easy to attain. Bias in protein 
data analysis is widespread and can be viewed as a threat to the validity of protein biomarkers 
where results have been unclear or irreproducible.
42,43
 This issue is apparent when handling 
large data sets, such as those presented in proteomic analyses. It is intrinsically easier to find a 
correlation irrespective of real cause and effect due to false positive probably outnumbering 
true positives.
34
 Lay et al. 
34
 pointed out that the failure of many proteomic studies correlates 
with the failure to consider the analytical need to define quality standards, including method 
validation and standardization. Also, due to a lack of quality standards, it is difficult to 
compare results generated from various laboratories.  
The analysis of a full proteome presents a formidable task and, in spite of recent 
technical developments, remains to be achieved for any species. The task is challenging 
because proteomes have a sizeable and undetermined complexity. What is certain is that the 
number of proteins in a species proteome exceeds by far the number of genes in the 
corresponding genome. This diversity arises from the fact that a particular gene can produce 
numerous distinct proteins as a result of alternative splicing of primary transcripts, the 
presence of sequence polymorphisms, posttranslational modifications, and other protein 
processing mechanisms.
44
 Moreover, proteins span a concentration range that surpasses the 
dynamic range of any single analytical method or instrument.  
Peripheral membrane proteins do not interact with the hydrophobic core of the 
phospholipid bilayer; they are usually bound to the membrane indirectly by interactions with 
integral membrane proteins or directly through ionic interactions with the lipid polar head 
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groups. Membrane proteins are, in some cases, amphipathic and can contain both hydrophobic 
and hydrophilic domains. These characteristics render them extremely difficult to analyze.
7
 
As a result, even though 20-30% of the human genome may encode for membrane proteins,
45
 
they are underrepresented in most analyses.
46
 
A central goal of proteomics has been the complete and, in most instances, 
quantitative analysis of the proteome of a species or, in multicellular organisms, a particular 
cell or tissue type. Although this goal has remained tenuous, significant progress has been 
made in the development of an array of technologies for proteome analysis and their 
application to biological and clinical research. At the present time, MS is generating the 
majority of proteomic data, more specifically by tandem MS (MS/MS) with increasing 
performance.
47
 The instrumentation and diverse workflows share a commonality in that they 
generate hundreds to thousands of fragment ion spectra per hour of data acquisition. However, 
the assignment of fragment ion spectra to peptide sequences, the interference of the proteins 
represented by the identified peptides, and the determination of their abundance in the sample 
being analyzed present complex statistical and computational challenges. Therefore, it is 
essential that tools and solutions that provide both accurate and reproducible results and can 
be generally applied to these problems be developed for proteomic studies.
47
 The 
determination of function and abundance of individual proteins is also critical.  
The correct assignment of the fragment ion spectrum to a peptide sequence is the first 
key step in proteomic data processing. A plethora of software tools and computational 
approaches have been developed to automatically assign peptide sequences to fragment ion 
spectra and can be classified into three categories: (i) Database searching; (ii) De novo 
sequencing; and (iii) alternative “hybrid” strategies. Database searching involves peptide 
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sequences being identified by correlating the fragment spectra that are acquired with 
theoretical spectra predicted for each peptide contained in a protein sequences database. In de 
novo sequencing, peptide sequences are clearly read out directly from fragment ion spectra. In 
addition, the alternative approaches that combine both database searching and de novo 
sequencing offer the option of performing “error-tolerant” database searching after the 
extraction of short sequence tags of 3-5 residues in length.  
Several MS/MS database search programs have been developed and take the fragment 
ion spectrum of a peptide as input and score it against theoretical fragmentation patterns 
constructed for peptides from the searched database. The group of candidate peptides is 
restricted based on user-specified criteria such as proteolytic enzyme constraint and mass 
tolerance.
47
 The output from the program is a list of fragment ion spectra matched to peptide 
sequences that have been ranked according to each score and, typically, the best scoring 
peptide match is considered during the subsequent statistical analysis step. The search score 
measures the degree of similarity between the experimental spectrum and the theoretical 
spectrum, and therefore serves as the primary discriminating parameter for separating correct 
from incorrect identifications.  
There are numerous scoring schemes available including spectral correlation functions 
(SEQUEST) or related concepts such as shared fragment counts and dot product (TANDEM, 
OMSSA, MASCOT).
47
 Scoring functions can also be based on empirically observed rules or 
statistically derived fragmentation frequencies. The score actually reported by the tool can be 
based on an arbitrary scale or converted to a statistical measure known as the expectation 
value, E, which refers to the expected number of peptides with scores equal to or better than 
the observed score under the assumption that peptides are matching the experimental 
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spectrum by random chance. The E value is computed by assuming that the database search 
score follows a particular distribution, i.e. Poisson, or by empirical fitting of the observed 
distribution of scores.
48-50
 This score is largely unchanged under different scoring methods 
and gives a clearer interpretation of quality of the match across different instrument platforms 
and search algorithms. However, it should be noted that neither the best match nor a high 
search score (or low E value) are reliable indicators for a true match. Discriminating true from 
false matches is therefore a critical next step in proteomic data analysis. 
  Spectral identification can be done using spectral matching with a library of spectra 
representing the peptide sequences contained in the proteome map.
51-53
 The spectral library is 
compiled from a large collection of experimentally observed mass spectra of correctly 
identified peptides. An unknown spectrum can then be identified by comparison to candidates 
in the spectral library to determine the match with the highest spectral similarity.
54
 Although 
the method of spectral matching outperforms database searching in speed, error rate, and 
sensitivity characteristics of the results, no peptides will be identified that were not previously 
entered into the respective spectral library. In the de novo sequencing approach, the amino 
acid sequence of a peptide is read from a fragment ion spectrum with the main advantage over 
database searching being that it allows identification of spectra for which the exact peptide 
sequence is not present in the searched sequence database, such as those peptides that contain 
sequences with modified peptides or polymorphisms.  
Yet, de novo analysis is computationally intensive and requires high quality fragment 
ion spectra. Furthermore, peptide sequences extracted using de novo algorithms need to be 
matched against sequences of known proteins present in the sequence databases because 
researchers are more interested in knowing the proteins present in the sample. Hybrid 
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strategies that combine both database searching and de novo sequencing start with the 
interference of short sequence tags (partial sequences) from MS/MS spectra, followed by an 
error-tolerant database search, which will allow for one or more mismatches between 
sequence of the peptide that produced the spectrum and the database sequence.
55-57
 By 
limiting the search to only those database peptides that contain the sequence tag extracted 
from the spectrum, the database search time can be reduced significantly. 
Although proteome analysis has seen various improvements over the last decade with 
respect to sample processing, data analysis, and data acquisition, many challenges remain. 
And are primarily associated with the complexity of the proteome itself. There are also 
challenges related to the analysis of the information contained in proteomic datasets. Inferring 
the identities of proteins, protein isoforms, and differentially modified proteins in a sample 
from confidently identified proteins is also a challenge. Two alternatives that are being 
utilized more frequently is top-down proteomics, which is focused on the analysis of intact 
proteins rather than the peptides and has the potential to resolve populations of proteins into 
their components,
58-60
 and the targeted analysis of specific peptides of high information 
content (proteolytic peptides) that collectively represent the proteome, thus eliminating the 
redundancy of current methods that are available now.
47,61,62
 Although substantial progress 
has been made in the effort to improve the analysis of proteomic data, the development of 
new algorithms and analysis tools still remain before these technologies can be implemented 
routinely. 
1.2 Membrane Proteins: Organelle-specific Sub-population of the Proteome 
 A strategy to overcome the challenges associated with full proteome analysis is to 
target proteomes of certain organelles, for example membrane proteins. Conventional 
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proteome analysis can include fractionation of biological cell components and performing the 
analysis on individual organelles
63
 such that only a sub-population of the full proteome is 
analyzed. Organelle pre-fractionation normally involves cell homogenization, density gradient 
separation of organelles, detergent extraction of membrane proteins, and two-phase 
partitioning with high-salt and high-pH washes. These processes can be lengthy, labor-
intensive, and may result in poor yields.
63-65
  
A principal sub-population of the proteome is membrane proteins, which provide 
important cellular functions such as controlling transport into and out of the cell and 
communication and regulating responses to external stimuli. Membrane proteins are normally 
classified into one of two categories, integral and peripheral and are based on the nature of 
their association with the cell membrane (see Figure 1.1).  
 
Figure 1.1  Various membrane proteins and their associations with the biological membrane 
(Reproduced from Cordwell, S. J.; Thingholm, T. E. Proteomics 2010, 10, 611
66
 with 
permission, Copyright 2013, John Wiley & Sons). 
 
 14 
Integral membrane proteins have domains embedded in the phospholipid bilayer and 
contain hydrophobic amino acid side-chain residues that interact with fatty acyl groups of the 
phospholipids, anchoring the protein to the membrane. They function primarily in signal 
transduction. Proteins that have domains that span the entire phospholipid bilayer are called 
transmembrane proteins. These molecules can possess several hundred amino acid residues 
that extend both into the aqueous medium on either side of the bilayer and multiple 
transmembrane domains (TMDs) within the membrane.
67
 Integral membrane proteins are, in 
most cases, amphipathic and can contain both hydrophobic and hydrophilic domains. These 
characteristics render them extremely difficult to analyze,
7
 and as a result, they are 
underrepresented in most analyses.
46
 Peripheral membrane proteins do not interact with the 
hydrophobic core of the phospholipid bilayer; they are usually bound to the membrane 
indirectly by interactions with integral membrane proteins or directly through ionic 
interactions with the lipid polar head groups.  
The isolation of sub-populations of the proteome can be combined with specific 
protein tagging strategies to reduce cross-contamination. For example, immobilized 
antibodies against membrane proteins were utilized for the purification of a membrane 
fraction using magnetic beads, but were limited to proteins for which a specific antibody was 
available.
68
 Protein radioactive labeling has been employed in different protein studies for the 
isolation of membrane proteins 
69
 and quantitative analysis of proteins by MS is often 
performed with isotope-coded affinity tags.
14
 Surface-protein biotinylation strategies with 
affinity purification using avidin or streptavidin columns, avidin-modified magnetic beads or 
visualized by hybridization with streptavidin-HRP complexes have been reported and new 




1.2.1 Importance of Integral Membrane Proteins 
Integral (or peripheral) membrane proteins act as major gateways into the intracellular 
environment. All cells and most intracellular organelles are enclosed in an impermeable lipid 
bilayer and the integral membrane proteins are embedded in these membranes. They are the 
entry and exit routes for many ions, nutrients, waste products, hormones, drugs and large 
molecules such as proteins and DNA. They are also responsible for much of the 
communication between cells and their environment. Additionally, these proteins provide 
responses to external stimuli. Cells can make a huge variety of membrane proteins. 
Approximately, 38% of all proteins encoded by the mammalian genome and more than one-
third of the current list of potential biomarkers are classified as membrane proteins.
77-79
  
The medical importance of this enormous family of proteins cannot be undervalued. 
Integral membrane proteins have been reported to play key roles in host-pathogen 
interactions
77,80-82
 and cell regeneration after injury.
83
 Cardiovascular diseases, cancer, and 
diseases caused by degeneration of cells within the central nervous system are major health 
problems in the United States.
77,84-86
 Proteomic investigations into Integral membrane proteins 
have the potential to identify new biomarkers that ensure early disease diagnosis, offer targets 
for new therapeutics, and provide an indication of response to therapy. 
 Integral membrane proteins are localized on the cell surface and are the first to be 
impacted by pathological changes in the cellular microenvironment. As part of the cellular 
response to a pathological insult, Integral membrane proteins may be secreted or shed from 
the cell surface into biological fluids (plasma, cerebrospinal fluid, or urine). 
87
 The level of 
Integral membrane proteins in these fluids can provide valuable diagnostic and/or prognostic 




As stated previously, membrane and membrane-associated cell surface proteins 
represent more than one-third of the proteins encoded by the human genome, however, they 
also account for more than two-thirds of the targets for existing drugs.
89
 They are also an area 
of special interest because of their accessibility to new drugs for treatment of the above-
mentioned diseases.
86,89,90
 Therefore, it is critical that advances toward the isolation and 
identification of Integral membrane proteins continue, especially those with multiple trans-
membrane domains (TMDs) and post-translational modifications (PTMs) due to their 
expansive roles as possible disease biomarkers and target molecules in disease treatment. 
1.2.2 Difficulties in Handling Integral Membrane Proteins 
 Membrane proteins are unique within proteome research due to their diversity and 
behavior during the process of purification and separation.
66,79
 Membrane proteins are 
embedded in the lipid bilayer and the composition of these lipids varies among the systems. 
The nature of the lipids can affect the stability of the protein. Several post-translational 
modifications (PTMs) of membrane proteins can produce extreme micro-heterogeneity that 
can reduce the efficiency of electrophoretic and chromatographic separations. The PTMs and 
hydrophobicity of Integral membrane proteins also cause complications with their 
identification by MS.
79,91
 Membrane proteins are extracted from the host cell membrane by 
the addition of detergents, which cover the hydrophobic surface of the protein, allowing 
solubilization. 
  The choice of detergent is a crucial part of the purification process. Often a series of 
detergents are tested and the detergent that extracts the largest quantity of soluble, active, 
homogeneous, stable protein is used; however, it should be noted that just because a detergent 
is successful with extracting membrane proteins, it does not mean that they will be 
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solubilized. Despite advances in methods to analyze hydrophobic proteins, integral membrane 
proteins are still under-represented in most membrane proteomes.
79,92
 Contamination of the 
membrane protein fraction by other organelles and non-membrane proteins, which interact 
with the plasma membranes during the purification process, is a serious issue. It is paramount 
that problems such as these be alleviated or eliminated to guarantee the purest membrane 
protein fraction for further downstream analysis. 
1.3 Current Methodologies in Integral Membrane Protein Analysis 
 The study of membrane proteins using high resolution and throughput proteomics 
remains challenging. While membrane proteins are generally low in abundance, the foremost 
impediment in their analysis is poor solubility. Integral membrane proteins, in particular, 
contain both hydrophobic and hydrophilic domains, which makes them difficult to purify and 
characterize on a proteomic scale. In order to undertake a comprehensive analysis of 
membrane proteins, several areas need to be considered. The analysis can be divided into four 
main experimental steps: (i) enrichment and purification of membrane proteins; (ii) 
solubilization of membrane proteins; (iii) separation; and (iv) identification and 
characterization (analytical techniques). Each of these steps provides experimental challenges 
and influences the success of the experimental design and the interpretation of the results. 
1.3.1 Enriching and Purifying Integral Membrane Proteins 
 There are several strategies available to probe targets that are in low abundance, 
including detection methods with single-molecule sensitivity that utilize fluorescence and/or 
electrochemistry. Mutch et al. developed a technique to count low-copy-number membrane 
proteins in synaptic vesicles.
125,126
 They used this approach to quantify proteins in isolated, 
single synaptic vesicles and they were able to quantify seven major membrane proteins of rat 
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brain synaptic vesicles. The method combined organelle purification with immunolabeling, 
microfluidics, and total-internal-reflection fluorescence (TIRF) microscopy. The enrichment 
and purification of integral membrane proteins is one of the most critical components of the 
experimental approach, with the major challenge being the presence of contaminating, higher 
abundance cytosolic proteins in the final protein extract prior to solubilization and analysis. 
Some of the strategies for the enrichment of membrane proteins are summarized in Table 1.1 
and will be discussed in the next few sections. 
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Table 1.1 Strategies for Membrane Protein Enrichment (continued) 
 
Many of the membrane protein fractions are obtained from tissue samples or cells that 
have been lysed by physical or chemical means.
66
 Membrane protein fractions with high 
purity and stringency are also hard to obtain from samples where little material exists to begin 
with.
66,93
 In studies with membrane proteins in which cell culture systems are utilized, often 
only Integral membrane proteins of the highest abundance are identified; and of those 
identified, many have poor reproducibility due to the presence of contaminating proteins from 
other organelles.
66
 Listed below are some the bench top techniques used for the enrichment 
and isolation of membrane proteins along with a short description as to their implementation. 
1.3.1.1 Precipitation and/or Density Gradient Centrifugation of Integral Membrane 
Proteins 
  
Sub-fractionation is a means for reducing the complexity of an initially complex 
sample, improving the dynamic range, and consequently enhancing the identification of low 




















































































the purification of membrane proteins involves density gradient ultra-centrifugation and/or 
chemical precipitation. Using chemical precipitation requires aqueous two-phase purification, 
where membrane and membrane proteins are separated from cytosolic (soluble) proteins 
according to their hydrophobicity, such as PEG 3350 or dextran T-500.
105,106
 Aqueous two-
phase purification has also been utilized for the fractionation of membrane proteins prior to 
MS analysis, resulting in the identification of 42% and 67% of integral membrane proteins of 
rat brain and liver proteins, respectively, as an example.
105,107
  
Density sedimentation or differential centrifugation of whole cell lysates, tissue 
lysates, or microsomes can be employed to separate membrane proteins from other sub-
cellular organelles due to their difference in density.
108-112
 Zhang et al. applied sucrose density 
gradient centrifugation to isolate membrane protein fractions from mouse liver, identifying 
50% of integral membrane proteins from a total of 175 proteins.
112
 Washing steps using high 
salt and high pH can improve the removal of cytosolic proteins, especially those that are 
loosely bound to the cell membrane.
113
 The combination of sodium carbonate extraction with 
sucrose gradient centrifugation has also been used to enrich for membrane proteins. With this 




Triton X-114 and other strong non-ionic detergents may also be used for the 
separation of extracted hydrophobic and hydrophilic proteins. The solution is homogenous at 
0°C, but separates into an aqueous phase and detergent phase when heated above 20°C with 
the separation becoming more apparent at increasing temperatures, and is also affected by the 
presence of other surfactants.
95
 The hydrophilic proteins separate to the aqueous phase and the 
hydrophobic membrane proteins are found in the detergent phase.
95
 This method has been 
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shown to be very efficient and has also been used for the separation of 
glycosylphosphatidylinositol (GPI)-anchored proteins.
115
 Thingholm and co-workers 
investigated the efficiency and reproducibility of combining sodium carbonate extraction with 
sucrose centrifugation for the enrichment of membrane proteins tested in the preparation for 
phosphorproteomic studies of human mesenchymal stem cell (hMSC) membrane proteins.
116
 
There are also commercially available methods such as the Mem-PER
TM
 Plus Membrane 
Protein Extraction Kit (Pierce Biotechnology, Rockford, IL) that use detergents to release 
cytosolic proteins into an aqueous phase and solubilize membrane proteins using detergents.  
However, it should be noted that although these studies employing two-phase 
purification, density sedimentation, or conventional differential centrifugation were successful 
in the confirmation of the enrichment of the integral membrane proteins, they have also been 
known to be contaminated with significant amounts of cytoplasmic organelles, making it 
difficult to compare protein expression profiles between two preparation methods.
75,114
 
1.3.1.2 Cross-linking of Integral Membrane Protein Complexes 
 Exposed integral membrane proteins can be purified using protein cross-linking 
reagents to maintain the membrane protein complexes as close to their native state as possible. 
After cell lysis, the non-complexed proteins can be removed by immunoprecipitation using 
antibodies directed against the membrane proteins of interest, size-exclusion chromatography, 
or through the use of a cross-linker that enables affinity purification.
66
 Several groups have 
employed this technique to get a better understanding of surface protein topology with protein 
complexes.
117
 A variation of this approach was introduced by Freed et al.
118
 that allowed for 
biotinylation and surface protein cross-linking. In turn, the strategy provided a robust means 
of affinity purifying the complexes that resulted from the cross-linking.  Recently, 
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photocrosslinking strategies have been utilized to improve the purification of membrane 
proteins.
119
 The study by Gubbens and co-workers employed cross-linking mitochondrial 
membrane proteins to phospholipids and led to the identification of several membrane 
proteins from the sub-sub cellular fraction.
119
 Their studies indicated that this approach could 
be an extremely effective way to further improve the identification of genuine membrane 
proteins. 
1.3.1.3 Cell-surface Shaving to Improve Identification of Integral Membrane Proteins 
The concept of cell-surface shaving for the improvement in identifying and 
quantifying proteins exposed on the cell surface has been discussed for quite some time.
120,121
 
The idea is formulated around using a protease in free solution around intact cells. Peptides 
that are exposed on the surface are cleaved by the protease into the surrounding solution. 




Figure 1.2 Cell ‘‘shaving.’’ Surface-exposed peptides are released by protease digestion into 
the surrounding solution. The peptides are then collected and analyzed by MS/ MS for their 
identification (Reproduced from Cordwell, S. J.; Thingholm, T. E. Proteomics 2010, 10, 611
66
 
with permission, Copyright 2013, John Wiley & Sons). 
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In theory, this method could prove to be very advantageous. First, it provides 
information about the surface topology of the cell (i.e. for those epitopes that are exposed on 
the surface, which are capable of interacting with other surface molecules, foreign particles, 
etc.). Furthermore, if proven successful, there would be no need for the solubilization of 
highly hydrophobic proteins because those peptides exposed on the surface would be soluble 
even from integral membrane proteins that are insoluble.  Unfortunately, cells have been 
unstable during the protease treatment when using this method. In addition, removal of cell 
debris is difficult when using centrifugation, and there has been significant contamination of 
cytoplasmic proteins after cell lysis. Yet, there has been some success when investigating 
bacterial systems (mainly Gram positive containing bacteria due the sturdy cell wall);
121,122
 
nevertheless, there are still a large amount of cytoplasmic proteins remaining on the identified 
protein lists, which reduces the confidence in the assignment of those epitopes exposed on the 
surface.  
There has been work by Speers and co-workers
123
 on HeLa cells using proteinase-K 
and high pH treatment combined with micro-LC-MS/MS performed at high temperatures. The 
authors reported a significant improvement in the identification of integral membrane 
proteins, with ~87% of those having transmembrane domains. Elortza et al.
124
 further 
modified the strategy and coined the term “shave and conquer” to describe phospholipase D 
treatment to remove GPI-anchored proteins from the cell surfaces of both plant and human 
cells. While there has been some success with this technique, it should be noted that problems 




1.3.1.4 Fractionation of Sub-cellular Organelles for Enrichment 
The current approach to proteomics is to assess fractions of organelles rather than cell 
homogenates by MS. As a result, the complex human proteome can be broken into simpler 
components. However, the quality of the data received relies heavily on the purity of the 
organelle fraction. There have been reports of more recently developed methods to generate 




For example, fluorescence-activated organelle sorting (FAOS), in which fluorescently 
tagged antibodies interact with highly expressed surface proteins that are specific to the 
organelle of interest, has been used to generate highly pure fractions.
127
 Gauthier et al. 
performed the proteomic analysis of the endocrine secretory granules of corticotropes-derived 
cells (AtT-20 cells) using FAOS.
128
 The authors circumvented the density gradient 
centrifugation steps. In order to purify the secretory granules, endocrine cells were transfected 
with a construct encompassing part of a secretory granule specific protein fused in frame with 
green fluorescent protein (GFP). Once sorted, the enriched secretory granules were lysed and 
their content was found to be closely related to that derived from other endocrine granules 
isolated through conventional density gradient protocols.
129
 Furthermore, MS analysis of the 
ensuing complex protein mixture was performed without resorting to gel electrophoresis, 
which, if deemed necessary, could add a further refinement step. 
1.3.1.5 Immunoaffinity Techniques for Enriching Integral Membrane Proteins 
 Affinity enrichment has also been used for the isolation of membrane proteins. In this 
case, enrichment was achieved through the use of silica or magnetic beads that have been 
coated with specific antibodies, a method that can be applied to both tissue samples and cells 
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grown in culture. Several groups have been successful in using immobilized monoclonal 
antibodies against known membrane proteins for enrichment.
130,131
 Moreover, the method is 
both an efficient and specific technique for additional purification of previously enriched 
fractions of membrane proteins. 
In 2004, Chang et al.
114
 developed a protocol for the isolation of neutrophil plasma 
membranes utilizing a plasma membrane marker antibody, anti-CD15, attached to 
superparamagnetic beads. Cells were initially disrupted by nitrogen cavitation and then 
incubated with anti-CD15 antibody-conjugated superparamagnetic beads. The beads were 
then washed to remove unbound cellular debris. These methods were coupled with 
immunodetection methods (Western blots) and an adenosine 5
′
-diphosphate-ribosylation 
assay to measure the amount of membrane-associated Giα proteins. Lawson et al.
101
 used the 
same technique in 2006 for the enrichment of membrane proteins from rat liver and two 
different hepatic carcinoma cell lines. Zhang and co-workers
132 
optimized an immunoaffinity 
protocol by using secondary antibody super-paramagnetic beads to enrich membrane proteins 
from mouse liver and compared the method to sucrose density centrifugation. Their optimized 
method showed a threefold increase in the amount of identified membrane proteins, and 
contamination of abundant, mitochondrial proteins was decreased. There has been a variation 
of this approach using cells that have been coated with antibody-conjugated magnetic beads 




1.3.2    Solubilizing Integral Membrane Proteins 
After successful enrichment of the membrane protein fractions, there still remains the 
issue of solubilizing the membrane proteins for further downstream analysis. Membrane 
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proteins are distributed in the lipid bilayers of cell membrane making them hydrophobic, but 
they also have hydrophilic regions that extend into the cytoplasm of the cellular region. They 
are very difficult to solubilize in water-based environments, because they easily form 
aggregates and precipitates in aqueous media;
134
 however, water-based environments are vital 
for IEF. Therefore, many other detergents, including Triton X-114, octylglucoside, CHAPS, 
C8Ø, sulfobetaines (SB 3-10, SB 3-12, etc.), and ASB-14,
8,135,136
 among others, have been 
employed to aid in the solubility of membrane proteins in aqueous solutions.  
Unfortunately, none of the detergents that are currently in place are satisfactory for all 
the membrane proteins.
135,136
 For example, C8Ø is good for isolating more abundant and 
hydrophobic membrane proteins, but not for a variety of critical membrane-associated 
proteins,
8
 which suffer loses after being processed with C8Ø. Secondly, proteins may 
precipitate at or close to their pI during IEF, where their solubility is lowest.
137
 Interactions 
between proteins with the acrylamide buffering groups resulting in adsorption of proteins in 




 utilized thiourea to alleviate this issue with 
hydrophobic membrane proteins. Nonetheless, protein loses still occurred due to thiourea 
inhibiting the SDS-protein binding, and, most importantly, increasing the solubility of lipids, 
which interfere with the isolation and separation of the membrane proteins in 2DE.
141,142
 
Additionally, there is a limitation on the use of reducing agents. Detergents can interfere with 
downstream processing (i.e. mass spectrometry) because they can have negative effects on the 
enzymes used for digestion. Some of the main methods for membrane protein solubilization 
discussed throughout this section are summarized in Table 1.2. 
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Many reducing agents have been employed for IEF, and each has its own drawbacks. 
Dithiothreitol (DTT), dithioerythritol (DTE), and tris(2-carboxyethyl) phosphine  (TCEP) are 
weakly acidic and are charged at alkaline pH, migrating towards the anode. Consequently, 
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there will be a deficiency at the basic end of the IPG strip during IEF and, in turn, will cause 
re-oxidation of reduced S-S bonds of the proteins and contribute to the horizontal streak.
143 
Repeated freezing and thawing is a technique that has been used to solubilize those 
proteins only loosely associated with the plasma membrane and not those with many 
transmembrane domains.
144 
Following extraction, various detergents must be used to 
solubilize those integral membrane proteins that are highly hydrophobic, but what detergent is 
used is dependent upon the downstream separation/fractionation techniques 
employed.
104,113,145,146
  It is vital that the known biochemistry of the system being investigated 
is taken into account. For example, the use of chaotropic reagents such as urea or guanidine 
hydrochloride, or strong ionic detergents such as SDS, may not be compatible with some 




Many groups have used liver tissue from rats as a model for membrane protein studies. 
One study combined sodium cholate and polidocanol to solubilize rat liver membrane proteins 






 Studies by Josic and co-workers
144,145
 have 
employed different solubilizing agents and Triton X-100. After the solubilization of the 
membrane proteins, they used an ethanol/acetone wash to remove lipids and precipitate the 
detergent-resistant proteins. The proteins were then subsequently solubilized with urea and 
the zwitterionic detergent CHAPS. Unfortunately, membrane proteins with several 
transmembrane domains were not solubilized.
148
 Prior to separation with SDS-PAGE and LC-
MS/MS, Clifton et al. utilized EGTA with octyl-glucopyranoside for the extraction of 
detergent resistant proteins.
149
 In a consequent study, the same group used a sequential 
extraction method by repeated freezing and thawing as the first step, followed by washes with 
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different salt solutions and/or high pH. Thirdly, the integral membrane proteins were 
solubilized with different detergents and finally, the proteins that were insoluble in detergent 




As previously stated, there are still many challenges with solubilization of integral 
membrane proteins because several suitable detergents and chaotropes used interfere with the 
downstream separations, particularly liquid chromatography (LC). In addition, if mass 
spectrometry is to be used (i.e. electrospray ionization, ESI-MS), the use of detergents can 
introduce noise into the analytical technique due to the chemicals there within, and thus, must 
be removed prior to analysis.
153 
Although methods exist to achieve detergent removal, they 
usually result in loss of analyte and are not necessarily compatible with studies that wish to 
examine samples with low yield or sample targets low in abundance.  
Detergent removal is typically done by precipitation of the proteins using 
trichloroacetic acid (TCA), a combination of chloroform and methanol, or with organic 
solvents such as acetone. Furthermore, in addition to the overall loss of proteins from the 
sample following precipitation, it is likely possible that hydrophobic proteins of interest are 
also lost during this step.
101,149
 Blonder et al.
153 
employed the combination of carbonate 
extraction and solubilization using organic solvent that was free of surfactants to avoid the 
loss of the hydrophobic proteins. They then followed with tryptic digestion prior to MS 







1.3.3  Separating Complex Fractions of Integral Membrane Proteins 
 After successful purification/enrichment of the membrane proteins and their 
solubilization, the sample is still complex and further fractionation is necessary in order to 
increase the eventual protein/peptide identification coverage, which is how many proteins are 
identified with the subsequent MS analysis. Methods of fractionation are typically focused on 
either separation at the peptide or protein level.
66
 There are various techniques available to 
perform protein separation including: two-dimensional electrophoresis utilizing IEF and SDS-
PAGE; SDS-PAGE coupled to liquid chromatography and tandem MS (LC/MS/MS) known 
as “slice and dice;” and methods for peptide separation after proteolytic digestion such as 
multidimensional peptide LC coupled to tandem MS and peptide isoelectric focusing (pIEF). 
1.3.3.1 Two-dimensional Electrophoresis (2DE) with Isoelectric Focusing (IEF) and 
SDS-PAGE for the Separation of Integral Membrane Proteins 
 
 For a number of years, the most popular method used for fractionation has been SDS-
PAGE,
155-157
 either as the sole method of separation, or in combination with IEF to produce a 
2DE technique (i.e. IEF in the first dimension coupled with SDS-PAGE in the second 
dimension) that can offer high peak capacities compared to a 1DE approach. While 2DE 
remains one of the core separation technologies of proteomic analysis, proteins that are 
extremely basic (positively charged), hydrophobic, or of large mass present significant 
challenges for 2DE separation due to aggregation, oxidation, precipitation, and the physical 
limitations of the 1D immobilized pH gradient (IPG) strip.
158
 Since the introduction of 
commercially available immobilized pH gradient strips, several groups have experimented 









McDonough and co-workers utilized modified equilibrium conditions between the 
IPG strip and the second dimension to get better focus and quantification of a positively 
charged integral membrane protein and also improved migration into the second dimension.
158
 
Techniques using IEF have enabled fractionation of proteins and peptides to be performed in 
solution, and new protocols have been developed using several detergents, thiol oxidation 
reagents, and different denaturants in order to make improvements to the isoelectric 
focusing.
141,159
 In order to provide enhanced sensitivity and improved reproducibility for 
peptide separations, IEF in IPG strips, free-flow electrophoresis, or in liquid isoelectric 
focusing has been used.
161,162
 
Chick et al. used an IPG-pIEF to identify 626 membrane proteins from rat liver, 
however, this only represented 42% of the identified proteins suggesting that there is a need 
for further investigation into enriched membrane proteomes in order to increase the 
identification rate of protein contamination from other sub-cellular fractions.
163
 Free flow 
electrophoresis has been used as a suitable approach for the separation of organelles, peptides, 
and proteins
164,165
 and has been shown to be highly reproducible, with excellent separation 
collecting up to 96 fractions.
162
 
There have been variations of the gel-based separation technique reported, such as the 
“slice and dice” method in which complex mixtures are separated by SDS-PAGE and the 
resulting gel is “sliced” into equal bands throughout the lane. Each band is then “diced” into 
smaller pieces and subjected to proteolytic digestion to release peptides that can be identified 
using reversed-phase (RP) LC-MS/MS.
66
 By utilizing this technique, hydrophobic proteins 
can be solubilized efficiently. Yet, 2DE employing IEF and SDS-PAGE have significant 
limitations at the protein level that minimize their effectiveness for membrane protein 
 32 
separation and 2DE usually offers poor resolution of hydrophobic or basic proteins especially 
those with > 3 transmembrane domains. 
 In work published by Xu et al.,
166
 the authors used IEF with SDS-PAGE to separate 
outer membrane proteins from E. coli. With this 2DE technique, they were able to obtain ~50 
spots that were representative of membrane proteins. The 2DE gel (IEF/SDS-PAGE) from the 
separation is shown in Figure 1.3. The spots that are more darkly stained are most likely 
representative of membrane proteins that are more abundant and the faint spots are those of 
membrane proteins that are lower in abundance. Several groups have attempted direct analysis 
of intact membrane proteins and identification of their covalent modifications. In this 
approach, the protein mixtures are first solubilized and then chromatographically resolved. 
Intact membrane proteins of up to 61 kDa
167-170
 have been analyzed directly by LC/MS.  
 
Figure 1.3 A 2DE profile of outer membrane proteins from E. coli employing IEF in the first 
dimension and SDS-PAGE in the second dimension (Reproduced from Xu, C.; Lin, X.; Ren, 
H.; Zhang, Y.; Wang, S.; Peng, X. Proteomics 2006, 6, 462
166
 with permission, Copyright 
2013, John Wiley & Sons). 
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le Coutre and co-workers
167
 employed high performance liquid chromatography 
(HPLC) coupled to electrospray ionization MS (ESI-MS) to separate and identify solubilized 
membrane proteins from E. coli. As the authors demonstrated (see Figure 1.4), 
chromatography combined with ESI-MS can separate an individual membrane protein from a 
crude mixture and measure its molecular mass, which can be used subsequently to identify the 
protein with a database search, provided the database sequence is correct and the isolated 
protein has not been post-translationally modified. 
 
Figure 1.4 (A) The elution profile of solubilized E. coli membrane proteins with HPLC. (B) 
ESI-MS spectrum of the peak indicated in panel A (Reproduced from le Coutre, J.; 
Whitelegge, J. P.; Gross, A.; Turk, E.; Wright, E. M.; Kaback, H. R.; Faull, K. F. 
Biochemistry 2000, 39, 4237.
167 
with permission, Copyright 2013, American Chemical 
Society). 
 
However, both methods have limited sensitivity making it difficult to detect lower 
abundance proteins, and the dynamic range is limited meaning that peptide-focused, liquid-
based strategies are more often used.
171
  
1.3.3.2 Separating Integral Membrane Proteins Utilizing Liquid Chromatography 
 To date, the most common method employed for the separation of integral membrane 
proteins or peptides from the proteolytic digestion of integral membrane proteins is high 
performance liquid chromatography (HPLC). Because of the complexity of biological 
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samples, a multi-dimensional separation approach is required in which various methods are 
combined.
22,172,173
 Strong cation exchange chromatography can be combined with reversed-
phase liquid chromatography (on- or off-line) for multi-dimensional protein identification 
technology (MudPIT), which can be directly coupled to a mass spectrometer for tandem MS 
(MS/MS) analysis.
22
 Wolters et al.
22
 utilized HPLC with MudPIT analysis to detect and 
identify proteins of the S. cerevisiae proteome. Integral membrane proteins are difficult to 
identify with 2D-PAGE, mainly due to solubility problems.
174
 Yet, unlike most other 
approaches, in the MudPIT scheme, protein digestion takes place first and thus overcomes 
protein solubility in solution or gel. In the analysis of the S. cerevisiae proteome via MudPIT, 
131 proteins with three or more predicted transmembrane domains were detected and 
identified.
22
 In addition, a highly efficient separation can be achieved due to the high loading 
capacity provided by strong cation exchange combined with the high resolving power of 
reversed-phase LC.
171,175
 This 2D LC strategy is routinely used for the analysis of integral 
membrane proteins since hydrophilic peptides from insoluble proteins are adaptable to rapid 
analysis. 
1.4 Analysis Strategies for Membrane Proteins 
1.4.1 Two Main Strategies for Mass Spectrometry Analysis of Proteins 
It would be preferable for a proteomic platform to quantitatively analyze the entire 
proteome in a high-throughput fashion, and do it with high sensitivity.
176
 There are two 
widely used approaches to protein analysis and identification: Bottom-up and top-down 
strategies. In the bottom-up approach, the intact protein mixture is directly subjected to 
proteolytic digestion (usually with trypsin) without first separating the proteins. In addition, 
proteins in complex mixtures can be separated before enzymatic (or chemical) digestion 
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followed by direct peptide mass fingerprinting-based acquisition or further peptide separation 
on-line coupled to tandem MS, which is then followed by the separation of the peptides, 
typically with liquid chromatography, with the isolated peptides being submitted for tandem 
mass analysis. 
A variation of the bottom-up approach is called “shotgun proteomics” because it is 
typically centered on early digestion of a protein mixture followed by a multidimensional 
chromatographic separation of the peptides and then coupled to a mass spectrometer for 
peptide mass determination. The essential difference in shotgun proteomics from the 
traditional bottom-up technique is that a non-separated protein mixture is digested instead of 
an isolated individual protein (see Figure 1.5). 
 
Figure 1.5 Overview of strategies for MS-based protein characterization and identification. 
Proteins extracted from biological samples can be analyzed by bottom-up or top-down 
methods. An on-line LC–MS strategy can also be used for large-scale protein interrogation 
(Reproduced from Han, X.; Aslanian, A.; Yates, J. R., 3rd Current opinion in chemical 
biology 2008, 12, 483.
177
 with permission, Copyright 2013, Elsevier). 
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In the top-down approach, proteins in complex mixtures are fractionated and separated 
into pure single proteins or less complex protein mixtures, followed by off-line static infusion 
of sample into the mass spectrometer for intact protein mass measurement and intact protein 
fragmentation.  
1.4.1.1 The “Top-Down” Approach 
 In the “top-down” approach, an individual protein mixture, or an individual protein, is 
digested.  This digestion generates peptides, which are more uniform and easier to analyze as 
opposed to a complex protein sample that contains a mixture of small, large, hydrophobic, and 
acidic/basic proteins and these extreme properties tend to yield poor 2D IEF/SDS-PAGE 
results
4
. Top-down MS is becoming a powerful technology for comprehensive analysis of 
protein modifications.
59,178-188
 In contrast to bottom-up MS, top-down MS analyzes intact 
proteins without proteolytic digestion as shown in Figure 1.6. This strategy preserves the 
labile structural characteristics that are mostly destroyed in bottom-up MS.
187
 It can 
universally detect all the existing modifications, including PTMs (i.e., phosphorylation, 
methylation, and acetylation) and sequence variants (i.e., mutants, alternatively spliced 
isoforms, and amino acid polymorphisms) concurrently in one spectrum (a “bird's-eye” view) 
without a prior knowledge.
187
  
Figure 1.6 Overview of the top-down proteomic strategy (Reproduced from Switzar, L.; 
Giera, M.; Niessen, W. M. Journal of proteome research 2013, 12, 1067
189
 with permission, 
Copyright 2013, American Chemical Society). 
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Top-down MS first measures the molecular weight of an intact protein and compares it 
with the calculated value based on the DNA-predicted protein sequence, which can easily 
reveal any changes/modifications in the protein sequence globally (the “top” part). Then, a 
specific modified form of interest can be directly isolated in the mass spectrometer (“a gas-
phase purification”) and subsequently fragmented in the mass spectrometer by tandem MS 
(MS/MS), such as collision-induced dissociation (CID) and electron-capture dissociation 
(ECD), for highly reliable mapping of the modification sites (the “down” part).
187,190
 The 
incorporation of the novel MS/MS technique, ECD,
191
 has greatly enhanced the capability of 
top-down MS in structural analysis of biomolecules.
192
 As a non-ergodic fragmentation 
method,
191
 ECD preserves labile PTMs during the fragmentation process; thus, it is 
particularly suitable for the localization of labile PTMs.
178,180
 In terms of an ionization source, 
electrospray ionization (ESI) is commonly used for top-down strategies, particularly because 
liquid chromatography (LC), used in the separation of the peptides, couples naturally to ESI 
due to the ability of continuous sample infusion into the ESI source.
193
 However, this 
continuous infusion of sample can overwhelm the mass spectrometer and cause a more 
complex peptide mass spectra to be generated. The top-down approach has the benefit of 
giving closer to full sequence coverage.
194
 Top-down approaches have been used to better 
understand the link between the observed changes and biological states of proteins.  
These links usually become clearer when studying the regulation of a protein’s 
function/activity achieved through changes in abundance, PTMs, balances in protein isoforms 
(different forms of the same protein that can arise from the same gene by alternative splicing 
or single nucleotide polymorphisms), cleavage of the proteins, and relocalization. In many 
instances, different isoforms are present and can lead to different activities or functions. It 
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should be noted that this approach requires high-resolution instrumentation such as FT-ICR 
MS, electron capture dissociation or electron transfer dissociation capabilities and reports 
have suggested that even quadrupole time-of-flight (Q-TOF) instrumentation can be modified 
to successfully undertake top-down approaches.
195
 
High-resolution instrumentation is needed because of the need to resolve the high 
molecular weights of intact proteins and protein mixtures with high complexity. The top-
down strategy has been successful in identifying post-translational modifications in individual 




 The sequencing of 
polymorphisms has also been done using this technique.
198
 Typically, intact proteins need to 
be extracted from cell/tissue lysate, solubilized, and separated/purified before MS analysis. 
Protein samples then need to be introduced to a mass spectrometer in buffer conditions 
compatible with MS analysis. 
The buffers employed to extract/solubilize proteins usually involve a high salt 
concentration, with the addition of detergents, such as SDS, Triton X-100, etc. to increase the 
solubility of the protein. These salts and detergents interfere with MS detection of proteins 
because they are present in large excess relative to proteins and have much higher ionization 
efficiency, which will, therefore, suppress protein signals. Standard procedures for detergent 
removal typically involve precipitation and resolubilization of proteins in detergent-free 
buffers, which may result in sample loss because some portion of protein may become 
insoluble in detergent-free buffers. Recently, there are efforts allocated in designing MS-
compatible acid labile detergents with the hope of replacing these traditional detergents.
198,199
 
Alternatively, proteins can also be selectively solubilized based on their inherent chemical 




 Moreover, these techniques can also be used to fractionate a specific sub-
proteome before chromatographic separation. 
Gel-based separation is widely used in bottom-up proteomics because trypsin-digested 
peptides can be effectively retrieved from gels.
201,202
 However, it is technically challenging to 
extract the intact proteins from gel matrices with a high recovery rate.
203
 Thus, gel-based 
separation is not applicable in top-down MS. Solution-based isoelectric focusing, coupled 
with a multiplex tube gel electrophoresis separation device, referred to as gel-eluted liquid 
fraction entrapment electrophoresis,
204
 has been developed for intact protein separation based 
on their MWs and applied to proteins (10–250 kDa) with a high resolution and a high 
recovery rate.
183,201,205
 Nevertheless, the surfactant SDS is still present in the sample so the 
proteins need to be precipitated in organic solvent and resolubilized in MS-compatible 
buffers. LC is ideally suited for proteomics because it can be conveniently interfaced with 
MS.
206-208
 The major LC techniques utilized for intact protein separation include affinity 
chromatography, ion-exchange chromatography, size-exclusion chromatography, and RP 
chromatography.
48
 Affinity chromatography has been one of the most effective and specific 
protein purification methods.
50
 For example, immunoaffinity methods have been used to 




Nonetheless, most of the affinity methods have been performed off-line, requiring an 
additional separation/desalting procedure using RPLC. Ion-exchange chromatography and 
SCX chromatography have also been used for intact protein separation.
206,211-213
 In addition, 
these separation techniques are used to perform the first-dimension separation, followed by 
RP chromatography in the second dimension. RP chromatography enhances the separation 
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from the previous step and performs desalting as the last sample preparation step before MS 
analysis.
212,213
 The 2-dimensional LC approach has the advantage of preconcentrating and 
desalting the species of interest simultaneously, yielding a higher peak capacity and better 
separation and, if connected on-line, minimizing sample loss. In contrast to the well-
established bottom-up proteomics, the top-down proteomics is still in its early developmental 
stage and has yet to fully overcome its technical challenges in sample preparation, instrument 
sensitivity/detection limit, and throughput/automation.
187,214-216
  
However, new technological developments are needed to advance top-down 
proteomics for the analysis of complex samples of cell/tissue lysate and biological fluid. 
Although the top-down approach is powerful in protein modification analysis, it is primarily 
performed with direct infusion of a single protein or simple protein mixture (separated off-
line), therefore, the analytical throughput and efficiency for large-scale proteome analysis is 
still a major challenge. To address these limitations, increasing efforts have been made to 
improve the front-end separation of complex protein mixtures and automated database 
searching informatics.  
1.4.1.2 The “Bottom-Up” Approach 
 The vast majority of proteomic studies are performed using the ‘bottom-up” approach. 
In this particular workflow (see Figure 1.7), after separation, intact proteins are cleaved using 
proteases such as Lysine C or enzymes such as trypsin, proteinase-K, or pepsin. Trypsin is 
most commonly used due to the fact that it is highly specific when cleaving the C-terminal 
side of lysine and arginine residues except when a proline is positioned directly on the C-
terminal side of the cleavage site.
66
 Furthermore, trypsin digestion for most proteins creates a 
series of peptides in a mass range that is compatible with nearly all MS instruments. However, 
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although trypsin is the ideal choice for a protease in most of these analyses, other enzymes 
have also been used as alternatives for digestion or used in parallel with one another to 
increase the overall proteome coverage.
218
 Proteins can also be cleaved utilizing enzyme-free 
approaches or by combinations of non-enzymatic hydrolysis.  
 
Figure 1.7 Overview of the bottom-up proteomic strategy (Reproduced from Switzar, L.; 
Giera, M.; Niessen, W. M. Journal of proteome research 2013, 12, 1067
189
 with permission, 
Copyright 2013, American Chemical Society) 
 
Bottom-up strategies are the standard for large-scale or high-throughput analysis of 
highly complex samples. There are usually two workflows associated with the bottom-up 
approach: “sort-then-break” and “break-then-sort.”
219
 The latter workflow involves protein 
digestion being conducted first without any prefractionation/separation step and then, the 
peptides are separated by multidimensional chromatography followed by tandem MS. In the 
“sort-then-break” approach, off-line protein fractionation and separation is performed first 
before protein digestion, followed by direct peptide analysis. 
When bottom-up analysis is performed on a mixture of proteins it is called “shotgun” 
proteomics, a term coined by the Yates lab
21,22
 because it is analogous to shotgun genomic 
sequencing.  Shotgun proteomics provides an indirect measurement of proteins through 
peptides derived from proteolytic digestion of intact proteins. In a typical shotgun proteomics 
experiment, the peptide mixture is fractionated and subjected to LC-MS/MS analysis. Peptide 
identification is achieved by comparing the tandem MS spectra derived from peptide 
fragmentation with theoretical tandem MS spectra generated from searching a database of 
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protein spectra. Protein interface is accomplished by assigning peptide sequences to proteins. 
Because peptides can be either uniquely assigned to a single protein or shared by more than 
one protein, the identified proteins may be further scored and grouped based on their peptides. 
Bottom-up strategies are suitable for automation, and high sample throughput can be 
achieved.
220-222
 These procedures typically identify a very limited number of peptides per 
protein, but still enough to identify the gene from which the protein was encoded. They work 
well in the study of microorganisms where the assumption that one gene codes for only one 
protein. However, when higher eukaryotes are investigated, processes including alternative 
splicing, RNA editing and post-translational modification can lead to several different protein 
species from a single gene. Peptide-based identification strategies enable the identification of 
the genes from which these proteins are derived. The bottom-up approaches generally do not 
provide information on the entire protein sequence, and similarly suffer from the fact that 
peptides from many possible forms of the parent gene products (arising from partial 
degradation and various covalent modifications) are generally indistinguishable in the absence 
of additional information (e.g., the MW of the parent protein). 
Multidimensional protein identification technology (MudPIT) is an automated bottom-
up approach in which the complexity problem is addressed at the peptide level.
22,221
 
Following enzymatic digestion of a total protein mixture, peptides are separated on a biphasic 
liquid chromatography column using a strong-cation exchange support as the initial phase, 
and subsequently reversed-phase material. The peptides are then delivered online to a tandem 
mass spectrometer, and MS/MS spectra are automatically detected for as many peptides as 
possible and those spectra used to search protein sequence databases. With this 
LC/LC/MS/MS procedure, a high-separation of peptides is achieved. The complex 
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deconvolution takes place mainly in the chromatography step, but the ability of the mass 




Two generally applicable bottom-up approaches for protein identification include one 
based upon mass measurements for a set of peptide digestion products from the parent protein 
and the other based on MS fragmentation (MS/MS) of one or more of these peptides. The first 
approach is referred to as peptide mass fingerprinting. A set of peptide fragments unique to 
each protein is created and their masses used as a ‘‘fingerprint’’ to identify the original 
protein. The peptide mass fingerprinting approach has been broadly applied with conventional 
MS instrumentation, but its throughput is limited because it requires prior isolation of a single 
protein (or a simple mixture). The second approach to protein identification is based on the 
information from dissociation (e.g., using collisional activation or some other energy 
deposition process) of one or more polypeptides that have typically been isolated by the first 
stage of the MS analysis.
224-225
 Furthermore, the entire bottom-up process can be laborious, 
time consuming, and limited to adopting automated processes.   
1.5 Advantages of Using Microfluidics for Proteomic Analysis 
 To minimize the disadvantages associated with bench-top strategies (i.e. time 
consumption, sample loss, automation, sample volume, etc.), researchers have been and are 
continuing to explore the use of microchips for proteomic analysis. There are several 
advantages toward the use of microfluidic platforms for proteomic analysis. Some of the key 
advantages of microfluidics are the miniaturization and integration of multiple process 
operations in a single device enabling (a) distinct processing steps without sample transfer, (b) 
shorter analysis times afforded by decreasing length scales without loss of efficiency and 
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reducing analyte diffusion, (c) handling of nanoliter volumes, (d) high-throughput processing, 
(e) a high degree of parallelization, and (f) automation of processing steps.
230
  
Devices like these offer the potential of enabling highly efficient, reproducible, and 
standardized proteomic workflows coupled with low sample consumption. Furthermore, 
process automation can diminish the need for highly trained analytical personnel, which is a 
vital attribute in clinical settings. Moreover, limiting manual input reduces the risk of 
contaminations, which has a major impact on the reliability of proteome analyses.
231
 In a 2011 
critical review, Liu and Fan discussed the attractiveness of thermoplastic microfluidic devices 
for both DNA and protein studies including immunoassays and protein separations.
232 
This is 
especially beneficial when the sample contains low abundant proteins such as integral 
membrane proteins. A high surface-to-volume ratio is afforded when miniaturized platforms 
are used, which is preferable in the case of protein extraction where the analyte-wall 
interaction is required especially for extraction onto a solid support. The mass transport is also 
improved for microfluidics due to smaller diffusional dimensions, which is advantageous for 
protein digestion or extraction. 
1.5.1 Survey of Reported Microfluidic Platforms for Protein Analysis 
Several microchip-based proteomic strategies have been demonstrated in the past 
decade, especially for integrating multiple processing steps onto a single platform for 
proteomic analysis. Summaries of microfluidic systems that have been used for the analysis of 






Table 1.3 Microfluidic Systems for Protein Analysis with processing devices combined prior 
to MS analysis 
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For example, Li et al.
227
 identified proteins from membrane-bound protein extracts of 
Haemophilus influenzae by separation of the proteome fraction first using 1D SDS-PAGE, 
then digesting the excised protein spots, and finally introducing the peptides into an integrated 
microchip consisting of capillary electrophoresis (CE) and nanoelectrospray. The use of 
surface coatings and a gold-coated nanoelectrospray tip allowed the microchip performance to 
be similar to a conventional nanoelectrospray CE in terms of LOD and the resolution per 
meter, yet faster due to the ease of creating shorter capillaries. 
The application of the device enabled the identification of peptides in tryptic digests of 
glycoproteins and further demonstrated that chip-based electrospray devices can be used with 
 46 
quadrupole time-of-flight mass spectrometry. The authors reported a concentration LOD of 
3.2-43.5 nM for different peptides and migration time and peak area reproducibility (i.e., 
RSD) of 3.1% and 6-13%, respectively. Musiyimi and co-workers
228
 developed a poly(methyl 
methacrylate), PMMA, CE chip that was directly coupled to a rotating ball for a MALDI-TOF 
MS analysis of protein digests. Mellors and Ramsey
229
 demonstrated electrospray MS directly 
from the corner of a glass chip without a nozzle (external tip) after CE. The CE-MS analysis 






In the work performed by Foote and co-workers,
230
 a microfabricated device with the 
ability to electrophoretically concentrate fluorescently labeled proteins prior to separation was 
developed (see Figure 1.8). The proteins were concentrated using a porous silica membrane 
between adjacent microchannels that allowed for the passage of buffer ions, but excluded 
larger migrating molecules. The concentrated proteins were then injected into a separation 
column for electrophoretic analysis. Pre-concentration factors of ~600-fold were achieved 
using this on-chip format, which was followed by a SDS µ-CGE separation of the proteins. 
The channels were filled with CE-SDS protein run buffer that was purchased from BioRad 
and allowed a current of ~1.2 µA when a voltage of 1 kV was applied between 
preconcentration reservoir 1 and the sample reservoir. Individual microchips were used for up 
to >200 preconcentration cycles using an applied voltage of 1 kV and an average 




Figure 1.8 (A) Schematic of microchip layout used for peptide preconcentration. (B) 
Microscopic image of preconcentrator-injector channels. (C) Schematic cross section through 
injector and preconcentrator channels (Reproduced from Foote, R. S.; Khandurina, J.; 
Jacobson, S. C.; Ramsey, J. M. Anal Chem. Preconcentration of Proteins on Microfluidic 
Devices Using Porous Silica Membranes. 2005, 77, 57.
230
 with permission, Copyright 2013, 




 described a glass microfluidic system for proteomics that included 
proteolysis directly coupled to affinity selection (see Figure 1.9). Their initial results using 
standard phosphopeptide fragments from β-casein in peptide mixtures showed selective 
capture of the phosphorylated fragments using immobilized metal affinity chromatography 
(IMAC) beads packed into a microchannel. The results showed selective capture of only 
phosphopeptide fragments, but digestion of protein was incomplete as indicated from multiple 
peaks in the CE separations. Application to digestion and capture of a serum fraction showed 




Figure 1.9 Diagram of an integrated trypsin digestion and affinity capture process along with 
a picture of the actual microdevice (Reproduced from Yue, G. E.; Roper, M. G.; Balchunas, 
C.; Pulsipher, A.; Coon, J. J.; Shabanowitz, J.; Hunt, D. F.; Landers, J. P.; Ferrance, J. P. 
Analytica chimica acta, Protein digestion and phosphopeptide enrichment on a glass 
microchip. 2006, 564, 116.
231
 with permission from Elsevier, Copyright 2013). 
 
An integrated poly(dimethylsiloxane) (PDMS) microchip for SPE and CE followed by 
ESI/TOF MS has been developed and evaluated by Dahlin and co-workers.
232 
The microchip 
(see Figure 1.10) was fabricated in a novel one-step procedure where PDMS was cast over 
steel wires in a mold. Once the wires were removed, they defined 50 µm cylindrical channels. 
Fused-silica capillaries were then successfully inserted into the structure in a tight fit 
connection.  The inner walls of the inserted fused-silica capillaries and the PDMS microchip 
channels were modified with PolyE-323 (a positively charged polymer) that is used to reduce 
protein and peptide adsorption on capillary walls during electrophoresis. In this approach, the 
chip was fabricated in a two-level cross design.  The channel at the lower level was packed 
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with 5 µm hyper-cross-linked polystyrene beads acting as a SPE medium used for desalting.  
The upper level channel acted as a CE channel and ended in an integrated emitter tip coated 
with conducting graphite powder to facilitate the electrical contact for ESI. 
 
Figure 1.10  (A) Schematic of a PDMS microchip device.  Channel A: sample inlet; Channel 
B: CE; Channel C: waste channel. (B) Schematic showing the instrumental setup and the 
connection of the microchip to the ESI/TOF MS (Reproduced from Dahlin, A. P.; Bergstrom, 
S. K.; Andren, P. E.; Markides, K. E.; Bergquist, J. Anal Chem. Poly(dimethylsiloxane)-
Based Microchip for Two-Dimensional Solid-phase Extraction-Capillary Electrophoresis with 
an Integrated Electrospray Emitter Tip. 2005, 77, 5356.
232 




To evaluate the microchip, six-peptide mixtures were dissolved in physiological salt 
solution, injected, desalted, separated, and sprayed into a MS for analysis with a limit-of-
detection in the femtomolar range. The applied CE voltage was varied from -6 to -16 kV with 
an increment of -2 kV for every injection, giving an electric field of -193 to -516 V/cm. An 
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integrated microfabricated system composed of a proteolytic reactor and chromatographic 
column with direct interface to ESI-MS was reported by Carlier et al.
233
 The system was 
fabricated from SU-8 and used to perform protein digestion, sample purification, salt removal, 
and chromatography followed by MS analysis. The chromatographic end of the chip was 
terminated with a nano-ESI interface. The digestion module was composed of trypsin 
covalently attached to a monolithic polymer, which was also used to prepare a hydrophobic 
stationary phase for the desalting or separation of peptides prior to MS analysis 
In a similar effort to combine preconcentration with electrophoretic separations,  
Fortier et al.
234
 investigated the analytical performances of a fabricated microfluidic device, 
which included an enrichment column, a reversed phase separation channel, and a 
nanoelectrospray emitter embedded together in polyimide layers. This configuration 
minimized transfer lines and connections and reduced post-column peak broadening and dead 
volume. The compact microchip was interfaced to both ion trap and TOF MS, and its 
analytical potentials were evaluated in the context of proteomic applications. Sensitivity 
measurements were performed on a dilution series of protein digests spiked into rat plasma 
samples and provided a detection limit of 1–5 fmol.  
Huft et al.
235
 fabricated a column geometry that allowed both robust and low-pressure 
packing of liquid chromatography columns in PDMS devices (see Figure 1.11). They 
combined the use of high-performance chromatography and valve-based microfluidics. The 
packing was achieved in minutes and enabled the integration of multiple parallel columns on 
a single device with high yield and without defects. The approach works by using microvalve 
control to reconfigure the columns for operation in either the packing or separation mode. The 
authors utilized pulse tests to show that the columns fabricated in this manner can achieve 
 51 
high efficiency and reproducibility. They also reported plate heights (for the separation of 
dye-labeled ssDNA) that were comparable to conventional high-performance capillary 
columns and plate numbers that exceeded 1,000,000 plates. 
 
Figure 1.11 Micrographs of solid-phase chromatography columns fabricated in PDMS. (a) 
before packing of the columns, (b) front of one column after packing, (c) back of same 
column from b with resin inlet closed, (d) bypass channels along a section of unpacked 
column, (e) section in panel d after packing, (f) resin inlet from c. (Reproduced from Huft, J., 
Haynes, C. A., and Hansen, C. L. Anal Chem 2013, 85, 1797.
235 
with permission, Copyright 






 both reported lab-on-chip techniques for separating and 
detecting protein mixtures. Gottschlich and co-workers integrated a microreactor, injector and 
electrophoretic separator and a second reactor for derivatization on a monolithic substrate 
followed by fluorescence detection. Liu integrated capillary electrophoresis, postcolumn 




a microfluidic device that integrated an electrospray ionization source for MS with a protein 
digestion bed, a capillary electrophoresis channel, and an injector on a monolithic substrate. 
The protein digestion bed had trypsin immobilized onto microbeads to permit faster digestion 
and to eliminate autodigestion products that might hinder sample characterization. 
1.5.2.1 Digital Microfluidics for Proteomic Analysis 
Microfluidic devices that can handle droplets can also perform a variety of functions 
(i.e. sorting, storage, and splitting) and can be integrated to MS or CE instrumentation.
240,241 
Digital microfluidics (DMF) is characterized by the manipulation of discrete droplets on 
hydrophobic, insulated electrode arrays that have no channels. When successive potentials are 
applied to the electrodes, droplet manipulations such as merging, mixing, splitting, and 
dispensing from reservoirs are facilitated.
242
 Because droplets are individually addressable 
and have individual boundaries, they can act as discrete microreactors. A DMF method was 
developed for the extraction and purification of protein from a complex biological sample by 
precipitation, rinsing, and resolubilization, with protein recoveries of roughly 80%.
243
 
Applications involving MS can also be used with DMF, which has increased its popularity in 
recent years. In-line coupling with DMF is a likely fit because both techniques require liquid 
samples and compatible volumes. Jebrail and co-workers reported the first in-line interface for 
DMF and nanoESI-MS.
244
 The device consisted of a DMF platform and a microchannel 
nanoESI emitter that was used for the quantification of amino acids from samples of dried 
blood spots. 
Another way to integrate (in-line) DMF and MS is to use a specialized ionization 
technique. Surface acoustic wave nebulization (SAWN) exploits the acceleration of acoustic 
waves that have propagated on the surface of a piezoelectric substrate and produces an aerosol 
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that contains solvated ions from a liquid droplet on the surface.
245
 Dennison et al. coupled 
SAWN to MS for top-down protein fragmentation studies.
246
 Luk and Wheeler reported an 




Figure 1.12 A sequence of images depicting the proteomic sample workup of the protein 
sample going through reduction, alkylation, and digestion on the DMF device. (a,b) Droplets 
containing insulin and TCEP merged are dispensed from reservoirs, merged and mixed. (c) A 
droplet of iodoacetamide being dispensed and merged with the sample droplet and mixed. 
After incubation (d) the sample droplet is merged with a droplet of trypsin for digestion and 
(e) final incubation. (Reproduced from Luk, V. N. and Wheeler, A. R. Anal Chem 2009, 15, 
4524.
247 
with permission, Copyright 2013, American Chemical Society). 
 
The device performed sample reduction, alkylation, and enzymatic digestion on a 
single platform and interfaced with MALDI-MS to qualitatively confirm the protein products 
from the reaction steps. This device is an excellent example of integrating multiple processing 
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steps in proteomics on a single platform for analysis. Luk and Wheeler have also used DMF 




Figure 1.13 Series of images from a movie and a schematic displaying the hydrogel 
proteolytic enzymes microreactors performing digestion in a 2-mm-diameter gel disc on a 
DMF device. (Reproduced and adapted from Luk, V. N.; Fiddes, L. K.; Luk, V. M.; 
Kumacheva, E.; Wheeler, A. R. Digital Microfluidic Hydrogel Microreactors for proteomics. 
Proteomics 2012, 12, 1310.
248 
with permission, Copyright 2013, American Chemical 
Society). 
 
The authors employed cylindrical agarose discs with immobilized trypsin or pepsin 
and integrated them into DMF devices. The 1 mg/mL BSA or lysozyme protein samples were 
sequentially reduced, alkylated, and digested with all sample and reagent handling controlled 
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by droplet operation. The MALDI-MS analysis of the products showed that by performing 
digestion in this manner, they were able to obtain higher sequence coverage.  
Digital microfluidics is not a cure-all for all MS applications, and there are still some 
challenges and limitations that need to be addressed before DMF becomes a widespread 
technique. Biofouling, which is a negative side effect of using high surface-to-volume ratios 
due to the increased rate of adsorption of analytes from solution to the solid surface, is 
problematic for DMF and can lead to cross-contamination. However, the drawbacks of 
biofouling have lead to significant improvements such as the use of oils to encapsulate 
droplets,
249,250
 the use of nanostructured super-hydrophobic surfaces or amphiphilic additives 
to limit adsorption,
251,252
 and films that are removable to prevent cross-contamination between 
steps. In spite of these challenges, DMF is still an emerging powerful tool for upstream 
sample processing in proteomic analysis. The ‘hands-off’ approach augments the ability to 
fully automate sample processing steps and analysis on a single platform, which makes DMF 
extremely attractive. 
1.6 More Efforts Toward On-chip Proteomic Processing  
The uses of spotted array-based tools have also garnered attention for proteomic 
analysis.
253
 In array-based methods, small spots of proteins are immobilized onto silicon-
based substrates (usually glass). The array can then be used to screen complex protein 
mixtures for particular binding affinities or other interactions. These arrays potentially address 
several concerns associated with the 2DE-MS (IEF/SDS-PAGE): the arrays can be used at 
little cost, provide consistently reliable and rapid results and are simple to use. Haab and 
colleagues
254
 utilized printed protein arrays to measure protein–protein interactions based on a 
fluorescence assay. Spotted arrays can also be used to probe protein–small molecule 
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interactions. Immobilized proteins are patterned onto a microscope slide using high-precision 
contact printing to deliver small quantities of protein to an aldehyde-coated glass surface.
255 
Using this system, spot densities of  >1600 spots cm
−2
 can be achieved with spot diameters of 
150–200 μm. This technology has been applied to the identification of protein kinase 
substrates and for screening protein–protein interactions.  
Surface-enhanced affinity capture, a promising version of surface-enhanced laser and 
ionization (SELDI) technology,
256
 uses probe surfaces to extract or structurally modify a 
particular protein. After the addition of a matrix solution to enhance laser energy transfer and 
sample ionization, samples are analyzed using TOF-MS. Advantages of this approach include 
a reduced amount of sample preparation before MS and the ability to capture trace amounts of 
proteins directly from biological fluids.  
Although these devices hold tremendous promise to address some of the limitations 
facing approaches for proteome analysis, they too have their own limits (i.e. fabrication, 
material compatibility, etc.). Much of the work mentioned here thus far deals with the analysis 
of known protein mixtures or peptides and not complex biological samples that contain 
membrane proteins.  
1.7 Concluding Remarks 
It should be noted that the majority of the aforementioned microfluidic systems 
analyzed peptides, model proteins, nucleic acids, or purified protein samples. Therefore, there 
is still a need for a proteomic platform that can analyze complex biological samples such as 
those containing integral membrane proteins or whole cell lysates. As previously stated, 
membrane proteins offer an abundance of possibilities for biomarker discovery, drug 
development, and treatment of various diseases such as cancer.  
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The need to understand the biological mechanisms involved in cancer and infectious 
and inflammatory diseases at the clinical levels implies not only comprehensive protein 
identification but also expression profiling of proteins across healthy and disease patient 
samples. In this context, the challenge of proteomics lies in the complexity of protein 
mixtures, the number of samples, and the reproducibility of analysis. Kotz and co-workers
257
 
developed a microfluidic device to isolate neutrophils directly from whole blood in order to 
process proteins for proteomic (mass spectrometry) studies (see Figure 1.14).  
 
Figure 1.14 Microfluidic device used for clinical genomic and proteomic studies. (a) 
microfluidic chip design and (b) schematic of the surface functionalization of antibodies to the 
device. (Reprinted and adapted from Kotz, K. T.; Xiao, W.; Miller-Graziano, C.; Qian, W. J.; 
Russom, A.; Warner, E. A.; Moldawer, L. L.; De, A.; Bankey, P. E.; Petritis, B. O.; Camp, D. 
G., 2
nd
; Rosenbach, A. E.; Goverman, J.; Fagan, S. P.; Brownstein, B. H.; Irimia, D.; Xu, W.; 
Wilhelmy, J.; Mindrinos, M. N.; Smith, R. D.; Davis, R. W.; Tompkins, R. G.; Toner, M. Nat 
Med 2010, 16, 1042.
257 
with permission, Copyright 2013). 
 
The authors demonstrated the scalability of the device as well as its application in a 
clinical setting. The microfluidic device was able to capture highly enriched (>95%) 
neutrophils directly from whole blood in ~5 min and in sufficient quantity and purity for mass 
spectrometry-based proteomic analysis. The proteomic samples were of high enough quality 
to discriminate between small differences in neutrophil activation states. Furthermore, the 
authors implemented the utility of the device in a clinical program and observed the changes 
in gene expression of neutrophils that are highly regulated after traumatic injury. 
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To date, there is still a need for a microfluidic system that can perform a complete 
proteomic analysis of a complex protein sample, especially those containing membrane 
proteins. When considering an integrated system such as those listed in the sections above, it 
is very important that the processes there within are compatible one another. It is critical that 
each step can operate independently, but there also cannot be interference between steps. For 
example, reagents used for extracting or isolating proteins in a sample must be compatible 
with subsequent separation and mass analysis steps. In addition, when investigating the use of 
a microfluidic system, it may be beneficial to take a step-by-step approach to ensure that the 
downstream processes are not negatively affected by those upstream. Improvements still need 
to be made in the area of protein enrichment and purification, which is a critical aspect of the 
work because as much material as possible is needed for the separation and the further 
downstream processes of protein digestion and subsequent peptide mass analysis since there 
is no procedure in place to amplify protein such as PCR for DNA. Much of the work 
mentioned previously involves off-chip protein enrichment strategies, which could result in 
loss of sample when moving on to subsequent analysis (i.e. separation, MS analysis, etc.).  
1.8 Research Objective 
The objective of this work was to design, fabricate, and characterize the operation of a 
fully integrated fluidic system that will serve as a foundation for a novel method to analyze 
proteins from complex biological samples based upon a top-down proteomic strategy. 
However, before integration is done, we must optimize each entity separately. Because 
enrichment is so critical in the case of low abundant proteins (i.e. integral membrane 
proteins), a module for the enrichment and purification of integral membrane proteins will be 
fabricated and will employ affinity techniques and microposts to extract membrane proteins 
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from whole cell lysate. This platform will be particularly useful for extracting only integral 
membrane proteins of interest through the use of a bioaffinity reactor based on the avidin-
biotin interaction. The use of this platform is two-fold as it will extract the integral membrane 
proteins and also purify the membrane protein fraction by excluding cytosolic proteins and 
nucleic acid material.  
The next step is the 2-dimensional CE separation of intact integral membrane proteins 
with μ-capillary gel electrophoresis (μ-CGE) in the first dimension coupled with micellar 
electrokinetic chromatography  (MEKC) in the second dimension. This module is based upon 
previous work performed in our group.
258,259
 The separation in the first dimension will be 
based on the molecular weights of the individual proteins and the second dimension will 
separate the proteins based upon their hydrophobicity and interaction with SDS micelles. We 
are taking a top-down approach because we want to separate the proteins intact and then do 
further analysis with MS. The two modules will be integrated, a module for digestion added, 
and coupled with MS based upon work previously done by Musyimi and Lee.
228,260
 Once 
completed, the fluidic system will offer researchers a fully integrated microfluidic platform 
for the complete analysis of integral membrane proteins from complex biological samples. A 
system of this nature will afford future opportunities for biomarker discovery, drug 
development, and diagnostics. 
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2 Solid-phase Extraction/Purification of Membrane Proteins from MCF-7 Breast 
Cancer Cells Using a UV-modified PMMA Microfluidic Bioaffinity µSPE Device 
 
2.1 Introduction 
 Membrane proteins play key roles in both the pathology and physiology of biological 
cells including: regulating the trafficking of ions and solutes in and out of the cell, cell-to-cell 
interactions, and responses to stimuli through surface receptors.
1
 Some specific modifications 
to membrane proteins have been linked to different pathologic states such as, cancer, 
neurological disorders, and diabetes.
2
 Because of these roles, membrane proteins have 
received attention as possible targets for the development of new therapeutics. 
Membrane proteins represent ~1/3 of proteins that are encoded by the human 
genome.
3,4
 Yet, only a small fraction of the cell surface proteome has been characterized
1,5
 
due to the difficulty in the handling of membrane proteins making their study challenging. 
Because of the interest in discovering and validating disease-specific protein signatures of 
diagnostic value or finding new drug targets discovery of personalized therapeutics, studies 
aimed at the identification, characterization, and quantification of membrane proteins has 
increased over the past few years. Most notably, several biopharmaceuticals (mainly 
antibodies) that target membrane proteins are already being used and studied for the treatment 
of tumors and lymphomas as well as some autoimmune diseases.
6
 
It has been difficult to analyze membrane proteins due to their low abundance, 
especially compared to the cytosolic proteins, their lower frequency of tryptic cleavage sites 
in the transmembrane domain,
6
 and the heterogeneity of membrane proteins.
7,8
 Therefore, a 
number of different approaches have been developed to address these issues. Methods that 
have been utilized for the isolation of membrane proteins specifically have exploited such 
analytical methods as ultracentrifugation,
9,10
 affinity selection of modified or non-modified 
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membrane proteins (antibody- or lectin-based approaches),
11,12





 Unfortunately, these methods have failed to produce highly pure isolates 
of the membrane proteins due in part to the large contamination from the cytosolic fraction. 
More recently, improved techniques for the enrichment of membrane proteins, both in vivo 
and in vitro, have been reported.
17
 These include the chemical capture of glycosylated 
membrane proteins,
18
 silica beads with the appropriate membrane protein-specific 
coatings,
19,20




The empirical formula of biotin was determined by du Vigneaud and co-workers
24
 in 
1941 and the structure was established by the same group in 1942.
25,26
 The Merck Research 
Laboratories confirmed the structure via total synthesis of racemic biotin.
27
 In 1966, x-ray 
crystallographic analysis established the absolute configuration of natural (+)-biotin as shown 
in Figure 2.1.
28
 The biotin-binding proteins avidin (from the egg white of birds, reptiles, and 
amphibians) and streptavidin (from the bacterium Streptomyces avidinii) have been employed 












Figure 2.1 Absolute configuration of natural (+)-biotin.  
 
Avidin (pI=10-10.5) has a mass of 67-68 kDa and is formed from four 128 amino 
acid-subunits with each subunit containing an epitope for biotin (see Figure 2.2) with all 
binding sites being stable over a wide pH and temperature range. Furthermore, avidin 
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maintains its high affinity to biotin in spite of the broad range of chemical modifications it can 
undergo making it useful for the purification of biotinylated molecules from complex sample 
matrices. Streptavidin (mass = 53 kD) has a lower pI (pI = 6.8-7.5) than avidin and is non-
glycosylated allowing a lower degree of nonspecific binding to it compared to avidin. 
Figure 2.2 Biotin–avidin Interaction: Biotin (green, red, and blue spheres) fits inside a pocket 
formed by a subunit of avidin protein (blue ribbon). (Reproduced from Weber, P. C.; 
Ohlendorf, D. H.; Wendoloski, J. J.; Salemme, F. R. Science 1989, 243, 85.
30
 with 
permission, Copyright 2013, AAAS). 
 
Streptavidin contains a bacterial recognition sequence called the RYD motif 
(tripeptide Arg-Tyr-Asp) that is similar to the mammalian RGD motif (tripeptide Arg-Gly-
Asp) that mediates cell attachment. This RYD motif can bind to cell surface receptors causing 
high background signals in certain samples. There is a deglycosylated avidin known as 
NeutrAvidin which has a lower mass (60 kDa) compared to avidin but retains the high biotin-
binding affinity. The deglycosylation of NeutrAvidin lowers the pI (pI = 6.3) and reduces the 
lectin binding to undetectable levels. In addition, lysine residues remain available and the 
NeutrAvidin can be derivatized or conjugated to a variety of targets at high loads. 
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NeutrAvidin also lacks the RYD sequence that streptavidin has so there is no risk of 
nonspecific binding. These advantages make NeutrAvidin attractive as the protein to use for 
biotin-binding assays.
7,31-35
 Table 2.1 summarizes the differences between the various biotin-
binding proteins. 


























































There are three essential components necessary for a reagent to be used for 
biotinylation: (i) a reactive moiety for the covalent attachment of biotin to a functional group 
on the chemical target(s). The most commonly used reactive moieties are esters, such as N-
hydroxysuccinimide (NHS), that can undergo a nucleophilic substitution reaction with 
primary amines (e.g. ε-amino group in exposed lysine residues present in proteins or 
peptides). (ii) The biotin moiety itself, which is used for the subsequent interaction of the 
biotinylated targets with the affinity-based reagent (avidin, streptavidin, or NeutrAvidin). The 
valeric acid side chain of biotin is important for the avidin association, but the carboxylic acid 
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group can also present on biotin can be derivatized to incorporate other reactive groups. 
Utilizing the biotin/avidin association can allow for the use of strong detergents during the 
purification/extraction steps without loss of material.
36
 (iii) A chemical spacer of adequate 
length to allow for efficient capture of the biotinylated targets with a solid phase in which 
avidin is covalently attached. The spacer, which is poised between the biotin molecule and the 
target, can improve biotin accessibility to its association partner by minimizing steric effects 
induced by the solid surface. The spacer may also contain a functional moiety that can be 
cleaved chemically or physically to aid in target release after extraction and purification of 
targets. 
In the past decade, several groups have used biotin/avidin affinity interactions to 
purify membrane proteins. In 2007, Tang and co-workers
33
 used three hydrophobic cell-
permeable chemical probes, which were designed and synthesized in-house on a modular 
scaffold for profiling the membrane proteome of S. oneidensis. Zhao et al.
35
 employed 
biotin/streptavidin to enrich plasma membrane protein fractions. The authors employed a 
hypotonic buffer and homogenization to lyse biotinylated cells from a human lung carcinoma 
cell line. After lysis, streptavidin-coated magnetic beads were added to the lysate suspension 
(see Figure 2.3). The beads were collected using a magnetic plate with the resulting fraction 
designated as the plasma membrane fraction. The plasma membrane fraction was washed with 
1 mL of 1 M KCl (high-salt wash), 0.1 M Na2CO3, pH 11.5 (high-pH wash), and finally with 
a hypotonic buffer. The method resulted in a 400-fold enrichment of plasma membrane 
proteins relative to the endoplasmic reticulum, which was a major contaminant in the plasma 




Figure 2.3 Overview of the assay utilized by Zhao et al. to enrich plasma membrane proteins 
from human lung carcinoma cells (Reproduced from Zhao, Y.; Zhang, W.; Kho, Y.; Zhao, Y. 
Anal Chem 2004, 76, 1817.
35 with permission, Copyright 2013 American Chemical Society). 
 
In this work, we present a novel method for the affinity enrichment of membrane 
proteins specifically using a microfluidic device for solid-phase extraction (SPE), which was 
made via hot embossing using a polymer substrate, in this case poly(methylmethacrylate), 
PMMA (µSPE device). The extraction bed contained micropillars that were covalently 
decorated with NeutrAvidin using EDC/NHS coupling chemistry between the NeutrAvidin 
molecules and the activated polymer surface; UV-activation (254 nm) of the polymer surface. 
Based on modification procedures of thermoplastics previously outlined in our group,
37
 the 
PMMA enrichment devices were exposed to UV light to generate surface-confined carboxylic 
acids followed by thermal assembly of the device. Neutravidin could subsequently be 
covalently strapped to the activated surface and used to select biotinylated proteins following 
cell lysis.  
This device was used for the solid-phase extraction and purification of membrane 
proteins from a whole cell lysate. The micropillars were used to increase the available surface 
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area to improve the dynamic range of the assay. As an example of the utility of the µSPE 
device, MCF-7 breast cancer cells and the extraction of the membrane proteins was evaluated. 
Intact MCF-7 cells were biotinylated using a reagent that contained a spacer moiety that could 
be cleaved to quantitatively release the enriched membrane fraction. 
Poly(methyl methacrylate), PMMA, was selected as the µSPE device substrate 
because of its ease of surface modification using UV light (254 nm), its biocompatibility, and 
the high surface density of functional groups it generates following UV activation. The µSPE 
device surfaces, including the micropillars, were decorated with NeutrAvidin via EDC/NHS 
coupling chemistry. We covalently attached biotin to extracellular primary amine groups of 
membrane proteins with the biotin providing an anchoring group for the affinity enrichment 
of these biotinylated proteins. The proteins were modified with sulfo-NHS-SS-biotin 
containing a disulfide-cleavable linker possessing a 24.3 Å spacer to reduce any steric effects. 
Washes with high salt and high pH solutions were used to remove interfering cytosolic 
species. Then, the bound membrane proteins could be released from the µSPE device by 
flooding the bed with a solution of 1,4-dithiothreitol (DTT) in a solubilization buffer. A 
Bradford assay was used to aid in the evaluation of membrane protein recovery and Western 
Blotting was performed to evaluate the presence of potential interferences from cytosolic 
proteins.  
2.2 Materials and Methods 
2.2.1 Fabrication of PMMA µSPE for Membrane Protein Enrichment 
Fabrication of the microfluidic device involved three major steps: (1) Mold insert 
fabrication using a micro-milling machine (Kern MMP, Kern Micro- and Feinwerktechnik, 
Murnau-Westried, Germany); (2) hot embossing of the microfluidic structures (HEX02, 
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JenOptik Mikrotechnik, Jena, Germany) into 3 mm thick PMMA substrates (Goodfellow, 
United Kingdom); and (3) post-processing of the microfluidic device including drilling of 
sample reservoirs, UV modification of the immobilization beds and cover plate assembly. The 
embossed device consisted of six, 24 mm long and 1.4 mm wide channels with microposts 
serving as the extraction bed. The post dimensions were 100 μm (height) x 100 μm (diameter) 
with a 50 μm spacing and a total of 3,600 microposts per bed. Each affinity bed had a total 
surface area of 110 mm
2
. Solution reservoirs were created by drilling 1 mm holes into the 3 
mm thick PMMA wafers.   
Thin PMMA sheets, 0.25 mm thick, were used to enclose the µSPE device by thermal 
fusion bonding. Prior to enclosure, the PMMA substrate was cleaned using isopropyl alcohol 
followed by sonication in ddH2O, then dried in an oven at 70ºC for 30 min. The PMMA 
substrate and cover plate were sandwiched between two borosilicate glass plates (McMaster, 
Atlanta, GA, USA) and clamped together prior to insertion into a convection oven. The 
thermal fusion bonding of the PMMA assembly was done at 100ºC for 20 min.  
2.2.2 Design and Operation of the µSPE Device 
 A variety of methods have been reported to introduce solid extraction phases into 
microfluidic devices, such as derivatization of microchannel walls with molecular reagents 
that bear the desired affinity agent, the use of polymeric membranes as sorbents, or the 
incorporation of magnetic or silica beads.
38
 The first demonstration of SPE in a microfluidic 
format was performed by introducing silica beads into a microchannel and was used for the 
analysis of amino acids and peptides.
39
 We have previously demonstrated a simple and 
effective method for creating high surface area extraction beds, which incorporate microposts 
embossed into a fluidic channel. This dramatically simplifies the fabrication process by 
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Figure 2.4 (A) Illustration of the topographical layout of the PMMA µSPE device showing 
the three beds with microposts used for the affinity capture of membrane proteins. (B&D) 
SEM images of the capture bed and a high magnification SEM (E) of the microposts. (C) A 
photo of the finished PMMA µSPE device.  
 
A schematic of the fluidic chip is shown in Figure 2.4A. Also shown are SEMs of the 
microposts poised within the affinity bed (B, D, & E), and a picture of the assembled device 
(C). Operation of the device involved 3 steps: (i) The sample was loaded into a syringe with 
the syringe connected via polyetheretherketone (PEEK) tubing (IDEX, Oak Harbor, WA) 
possessing a length of 9 cm (177 μm ID) to the input and output reservoirs of the µSPE device 
(see Figure 2.4C); (ii) the sample was dispensed into the reservoirs by loading wit a syringe 
pump (Harvard Apparatus, Holliston, MA); and (iii) the effluent was collected in 
microcentrifuge tubes. The affinity bed was washed with buffer solutions by manual loading. 
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The washing steps were critical in order to remove residual amounts of cellular debris that 
could potentially interfere with downstream analysis of the membrane proteins.  
2.2.3 Surface Modification of the PMMA µSPE Device 
The functional scaffold for NeutrAvidin attachment to the PMMA surface was built 
using a photochemical method (see Scheme 1). In this method, the affinity beds and cover 
plate were irradiated with a UV light source (22 mW/cm
2
; 254 nm) for 15 min using a low 
pressure Hg lamp (GLF-42, Jelight Company Inc., Irvine, CA). After thermal fusion bonding 
of the cover slip to the device, the channel was filled with a buffered solution of 0.05 M 2-(N-
morpholino) ethanesulfonic acid (MES, pH 5.0) containing 60 mg/mL of 1-ethyly-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and 6 mg/mL of N-hydroxysuccinimide (NHS). 
The solution was allowed to react with the surface at room temperature for 30 min to obtain a 
succinimidyl ester intermediate.  
Scheme 1 shows the photochemical modification of the surface of the µSPE device 
and the subsequent immobilization of NeutrAvidin via the EDC/NHS coupling reaction. 
Scheme 1 also describes the surface chemistry for the EDC/NHS coupling and the 
intermediates that are formed along with the amide bond that is used to immobilize 
NeutrAvidin to the pendant PMMA surface-confined carboxylic acids that are formed 
following UV activation. Figure 2.5 shows images of pristine PMMA, UV-modified PMMA, 
and the PMMA surface with immobilized NeutrAvidin that were taken using brightfield and 







Scheme 1 Reaction processes and intermediates formed on the PMMA surface during the 
EDC/NHS coupling reaction and NeutrAvidin immobilization. 1. Carboxylic acid; 2. EDC; 3. 
O-Acylisourea active intermediate; 4. NHS; 5. NHS-Ester intermediate; 6. Primary Amine-
containing molecule (i.e. NeutrAvidin); 7. NHS; 8. Amide bond formation. 
 
 
After the EDC/NHS reaction had incubated with the activated affinity bed surface for 
30 min, the surface was rinsed with 1x PBS (pH 8.0) to remove excess EDC/NHS. Next, a 
100 μL aliquot of 8 μM NeutrAvidin (in PBS, pH 8.0) was introduced into the extraction bed 
using manual loading with a syringe. The reaction was allowed to proceed overnight at 4ºC, 




Figure 2.5. Images of the affinity surface: A) Before UV modification (10x, brightfield); B) 
after UV modification (10x, brightfield); C) after NeutrAvidin immobilization (20x, 
brightfield); and D) after NeutrAvidin immobilization (20x, fluorescence at 488 nm). All 
images had an exposure time of 300 ms. 
 
Using a calculation from Lahiri and co-workers,
41
 we were able to determine the 
theoretical estimate of the maximal amount of immobilization for NeutrAvidin corresponding 




) per square millimeter 
that can be close packed in a hexagonal arrangement. We assume that the NeutrAvidin 
molecules are hard spheres with a radius of 2.6 nm. From the calculation, we found that 6.85 
pmol/cm
2
 was the theoretical maximum density of NeutrAvidin that could be immobilized 
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2.2.4 Mem-PER™ Plus Membrane Protein Extraction Reagent Kit 
In order to provide a direct comparison of the µSPE device and the associated assay to 
a currently available method for membrane protein extraction, a protein extraction kit 
available through Pierce Biotechnology (Rockford, IL) was utilized to extract membrane 
proteins from MCF-7 cells. The kit was used for the enrichment of integral membrane 
proteins and membrane-associated proteins from cultured mammalian cells or tissue and 
employs a detergent-based extraction protocol, which eliminates the use of phase separation 
based solely on hydrophobicity. The cells were permeabilized with a detergent to allow 
release of soluble cytosolic proteins from the membrane proteins. A second detergent was 
then used to solubilize the membrane proteins.  
Approximately 5 × 10
6
 cells were harvested from the culture dish and were 
centrifuged at 300× g for 5 min. Then, the pellet was washed with 3 mL of a cell wash 
solution and the resultant solution centrifuged at 300× g for 5 min. The supernatant was 
removed and discarded and the cell pellet was resuspended in 1.5 mL of Cell Wash Solution 
and transferred to a centrifuge tube and centrifuged at 300× g for 5 min with the supernatant 
discarded. Next, 750 μL of Permeabilization Buffer was added to the cell pellet and briefly 
vortexed to obtain a homogeneous solution. The pellet was then incubated at 4ºC for 10 min 
with constant mixing. After incubation, the cells were centrifuged at 16,000× g for 15 min 
with the supernatant discarded, which contained the cytosolic proteins. Once the cytosolic 
proteins were removed, 500 μL of the Solubilization Buffer was added to the remaining cell 
pellet and the cells were resuspended. The cell pellet was then incubated at 4ºC for 30 min 
with constant mixing. Lastly, centrifugation was done at 16,000x g for 15 min at 4ºC. The 
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remaining supernatant contained the solubilized membrane and membrane-associated 
proteins.  
2.2.5 Sample Preparation 
2.2.5.1 Cell Biotinylation and Lysis 
The biotinylation of the membrane proteins was performed on the intact MCF-7cells 
using a membrane impermeable reagent. As a result, only membrane proteins should be 
biotinylated, reducing the contamination of cytosolic proteins and other cellular material. The 
MCF-7 cells, an invasive breast ductal carcinoma, were utilized as a model in these studies. 
The biotinylation reagent Sulfo-NHS-SS-Biotin (molecular weight of 606.69 g/mol), 
Sulfosuccinimidyl-2-(biotinamido)-ethyl-1,3'- dithiopropionate, (Pierce Biotechnology, 
Rockford, IL) is membrane impenetrable and also contains a disulfide-cleavable linker 
possessing a 24.3 Å spacer to reduce any steric effects caused by the NeutrAvidin support and 
the biotinylated membrane proteins. 
 
Figure 2.6 Structure of NHS-SS-Biotin with the 24.3 Å spacer. 
The MCF-7 adherent cells were first washed with ice-cold 1x PBS (pH 8.0) three 
times to remove any amine contaminants and culture media from the cells. The cells were 
then suspended at a concentration of 5 x 10
6
 cells/mL in 1x PBS (pH 8.0). Immediately before 
use, a 10 mM solution of Sulfo-NHS-SS-Biotin was prepared by adding 164 μL of ultrapure 
water to 1 mg of the biotinylation reagent. Approximately 80 μL of the biotinylation reagent 
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was added per milliliter of reaction volume (volume added = 160 μL). The reaction was 
incubated at room temperature for 30 min with constant mixing. After incubation, the cells 
were washed with 1 mg/mL of lysine (pH 8.0) to quench the reaction by coupling to any non-
reacted biotinylation reagent and then washed two times with ice-cold 1x PBS (pH 8.0) to 
remove any remaining contaminants. The cells were then centrifuged at 300× g for 10 min 
(4ºC) to obtain a pellet. A fluorescence image (taken at 488 nm) of intact and biotinylated 
MCF-7 cells is shown in Figure 2.7.  
 
Figure 2.7 Fluorescence images taken at 488 nm (200 ms exposure time) of biotinylated 
MCF-7 cells that have been stained with FITC- conjugated avidin to show that the cells were 
biotinylated. 
 
After washing, a 4% CHAPS buffer, 7M urea, 2M thiourea, 30 mM Tris and 5 mM 
magnesium acetate (pH 8.5) were added to the pellet to lyse the cells. Dialysis was performed 
overnight with two buffer changes of 4% CHAPS (4ºC) to further remove excess biotin. 
Biotin incorporation was estimated using HABA, 2-(4’-hydroxyazobenzene)-2-carboxylic 
acid. The method is based on the ability of HABA to bind to avidin to form a complex with a 
maximum absorption at 500 nm. A sample containing biotinylated targets is added to the 
20x, 20 µm  20x, 20 µm  
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HABA-avidin solution and because of biotin’s higher affinity for avidin, it displaces HABA 
and the absorption at 500 nm decreases proportionately.
42
 The absorbance of the HABA-
avidin solution is measured before and after adding the biotinylated sample with the change in 
absorbance related to the amount of biotin present in the sample. Based on the absorbance 
measurements from the cells that were biotinylated, it was determined that there were 
between 2-3 biotin molecules per protein molecule. 
2.2.5.2 Western Blotting Analysis 
We determined the concentrations of both the membrane proteins and cytosolic 
proteins from the extraction procedure using a Bradford assay which used 8.2 μg of each 
protein fraction (membrane, cytosolic, and total lysate). Gel runs for the blotting assay 
employed the BioRad Mini-PROTEAN System (BioRad, Hercules, CA, USA). The procedure 
we followed is summarized below.  
A 3x Laemmli sample buffer (6% SDS, 30% glycerol, 187.5 mM Tris, 15% β-
mercaptoethanol, 0.006% bromophenol blue) with a 5 mL total volume was added to each 
protein fraction in order to prepare them for gel electrophoresis. The fractions were heated at 
95°C for 5 min, cooled on ice and briefly vortexed before being placed on the gel. A 4-15% 
BioRad precast gel was used along with a PageRuler Prestained Protein Ladder (Pierce 
Biotechnology, Rockford, IL, USA) that had a molecular weight range of 10-250 kDa. The 
running buffer (Tris/Glycine/SDS) was used to rinse the wells of the gel and the gel was 
placed in the gel box along with the running buffer. Five μL of the PageRuler was added to 
the well and 50 μL of each protein sample was added to the remaining wells. The gel was run 
for ~35 min at 200 V until the dye front could no longer be seen. 
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While the gel was running, a PVDF membrane was prepared by incubating in 
methanol for 30 s, rinsed briefly in ddH2O and then incubated in ice-cold transfer buffer (20% 
methanol, 10x Western Transfer Buffer, ddH2O) for 5 min. The gel was removed from the 
cassette case and placed on the PVDF membrane and both were sandwiched together with a 
transfer cassette. The PVDF/gel was placed back into the gel box along with the transfer 
buffer and run again for 70 min at 250 mA. When the run was completed, the membrane was 
removed from the cassette and rinsed briefly with a Tris-buffered saline and Tween-20 buffer 
(0.1% TBST, Tris-buffered saline, Tween-20, ddH2O). The membrane was blocked in 5% 
milk (dry milk, 0.1% TBST) for 1 h. The membrane was then incubated overnight at 4°C with 
the primary antibody (Anti-beta-actin antibody) in 5% dry milk and 0.1% TBST.  
After incubation, the antibody solution was decanted from the membrane. The 
membrane was washed 5 times for 5 min with the 0.1% TBST buffer and blocked for 5 min in 
5% milk. The membrane was incubated for 1 h at room temperature with the secondary 
antibody in 5% milk. The stock secondary antibody solution was diluted 1:5000 with a milk 
solution (1 μL anti-actin secondary antibody + 5 mL 5% milk). The membrane was washed 
again with 0.1% TBST (5 times, 5 min) and once for 5 min with 1x Tris-buffered saline 
(TBS).  
Enhanced chemiluminescence (ECL) was employed for detection of the resultant 
bands. The method works by detecting horseradish peroxidase (HRP) tethered to the 
secondary antibody forming an enzyme complex. The complex catalyzes the conversion of 
the chemiluminescent substrate into a sensitized reagent in the vicinity of the antibody, which 
on further oxidation by hydrogen peroxide produces a triplet (excited) carbonyl that emits 
light when it decays to the singlet carbonyl. ECL allows detection of minute quantities of a 
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biomolecule; proteins can be detected down to femtomole quantities. Once the ECL solution 
was prepared, the membrane was placed side up on a piece of plastic wrap and 2.5 mL of the 
ECL solution was pipetted over the membrane and incubated for 5 min making sure that no 
part of the membrane dried out. The membrane was removed from the ECL solution and 
excess solution was carefully blotted away. The membrane was placed in a plastic sleeve and 
lightly taped in place. The blot was exposed to film in a darkroom for 30 s and visualized. 
2.3 Results and Discussion 
2.3.1 Solid-phase Extraction/Purification of Biotinylated MCF-7 Cell Surface 
Membrane Proteins with Microfluidic Bioaffinity µSPE Device 
 
Previously reported methods for purifying membrane proteins from complex samples 
have combined the isolation of membrane proteins with specific protein tagging strategies to 
minimize cross-contamination. For example, antibodies directed against certain membrane 
proteins were immobilized onto magnetic beads and used for the purification of specific 
membrane proteins. Unfortunately, this method was limited to proteins for which a specific 
antibody was available.
43
 Protein radioactive labeling has also been employed in different 
protein studies,
44
 and quantitative analysis of proteins by MS was often performed with 
isotope-coded affinity tags.
45
 In 2002, Sabarth et al. used the hydrophilic reagent, S-NHS-LC-
biotin (sulfosuccinimidyl-6-(biotinamido)hexanoate), to biotinylate surface proteins of E. coli 
with enrichment via avidin-affinity chromatography.
31
 As previously mentioned, commercial 
kits for the extraction of membrane proteins with the use of detergents exist, however, they 
can potentially possess a high degree of cytosolic contamination that can complicate 
identification of the membrane proteins due to the relatively higher abundance of the cytosolic 
components. 
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The steps employed in our µSPE device and assay of membrane proteins from whole 
cell lysates are shown in Scheme 2. In the first step, modification of the PMMA surface 
followed by immobilization of NeutrAvidin is undertaken. Once the surface has been 
decorated with NeutrAvidin, the affinity bed is ready for infusion of the biotinylated proteins. 
 
Scheme 2 Overview of the on-chip extraction/purification assay for membrane proteins from 
cell lysates. Prior to cell lysis, the intact cells were biotinylated. 
 
For the present set of experiments, the cell lysate was infused into the affinity bed at a 
flow rate of 5.0 μL/min to allow sufficient time for the biotinylated proteins to interact with 
the surface-confined NeutrAvidin. The surface was then rinsed with a high salt/high pH wash 
to remove any loosely-bound cytosolic proteins. Following the wash, 300 mM DTT (in 4% 
CHAPS) was infused continuously for 2 h through the µSPE bed. The surface was finally 
 95 
rinsed with 1x PBS (pH 8.0) and the effluent containing the released membrane proteins 
collected for further analysis. The cell lysate originating from 5 x 10
6
 MCF-7 biotinylated 
cells in 4% CHAPS buffer was infused through the affinity bed of the µSPE device. To 
determine if the biotinylated proteins had indeed been captured by the surface-immobilized 
NeutrAvidin, we employed avidin labeled with FITC to visualize the affinity surface after 
infusion of the cell lysate through the device. The FITC-labeled avidin could bind to any 
available sites remaining on the biotinylated proteins that were not complexed to the surface-
confined NeutrAvidin molecules. Figure 2.8 shows fluorescence images of membrane 
proteins captured on the surface of the bioaffinity device after flooding the bed with FITC-
labeled avidin. 
 
Figure 2.8 Images A and B showing captured membrane proteins on the UV/NeutrAvidin-
modified PMMA capture surface. All images were done at a 300 ms exposure time with 
fluorescence done at 488 nm with FITC-labeled avidin 
 
Figure 2.8A & B show the immobilized membrane proteins at two different 
magnifications. As shown in Figure 2.8, fluorescence did appear within the affinity beds that 
were infused with the MCF-7 lysate. However, the resultant fluorescence appeared to be 
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globular and patchy on the surface of the micropillars. This data suggested that the membrane 
proteins were not well solubilized using only the 4% CHAPS buffer system before infusion 
into the affinity bed as well as possibly being partially associated with the cell membrane. 
Thus, it appears that the 4% CHAPS buffer was not sufficient for both cell lysis and 
solubilization. 
To further aid with the solubilization process, a proprietary solubilization buffer 
(Pierce Biotechnology, Rockford, IL) was added to the cell lysate after biotinylation and lysis 
with 4% CHAPS. The addition of this solubilization buffer proved helpful in solubilizing the 
membrane protein fraction. The results of this new solubilization procedure are shown in 
Figure 2.9. As shown in the fluorescence image, the resulting fluorescence was more 
homogeneous around the surface of the pillars containing NeutrAvidin instead of “patchy-
like,” and globular as noted in Figure 2.8.  
 
Figure 2.9 Images of the UV/NeutrAvidin-modified PMMA capture surface after the addition 
of solubilization buffer to the MCF-7 cell lysate. Images A, B, and C were taken at 10x, 20x, 
and 40x magnification, respectively and all images were done at a 300 ms exposure time. 
Fluorescence was done at 488 nm with FITC-labeled avidin. 
 
This result indicated that this lysis and solubilization procedure was much more 
effective than the case of using 4% CHAPS only. Also, as can be seen from these images, the 
fluorescence was visible from all of the pillars in the microscope field-of-view with all sides 
Flow Flow 
10x, 100 µm 20x, 50 µm 40x, 25 µm 
Flow 
A B C 
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of the pillar showing fluorescence. Therefore, we are operating with a load of protein 
(originating from 5 x 10
6
 MCF-7 cells) that saturates the affinity surface. 
 
Figure 2.10 Fluorescence at 488 nm (300 ms exposure time) of the μ-SPE surface after 
NeutrAvidin immobilization and flooding the bed with avidin-FITC to check for non-specific 
adsorption of the FITC-labeled avidin on the surface. 
 
To make sure that the resulting fluorescence shown in Figure 2.9 did not result from 
non-specific adsorption of the fluorescently labeled avidin to the PMMA micropillars, we 
subjected the NeutrAvidin-immobilized affinity bed to a solution containing the FITC-labeled 
avidin without the bed being subjected to the biotinylated proteins.  No fluorescence from the 
FITC-labeled avidin was observed (see Figure 2.10) indicating that there was no non-specific 
adsorption. 
2.3.2 Release of Captured Biotinylated Membrane Proteins from the µSPE Surface 
  
After affinity selection of the biotinylated membrane proteins by the µSPE device, a 
300 mM solution of DTT (in 4% CHAPS) was continuously infused into the SPE bed at a 
flow rate of 5.0 μL/min for 2 h to release the selected membrane proteins by reducing the 
 98 
disulfide bond carried in the Sulfo-NHS-biotin reagent. Infusion was done in the dark to 
prevent photobleaching of the FITC on the surface. A total of 100 μL of a rinsing effluent (1x 
PBS, pH 8.0) was infused. The chip was then imaged at a 20x magnification using a 
fluorescence microscope with excitation at 488 nm and a 300 ms exposure time. The resulting 
image is shown in Figure 2.11. As shown, there was no visible fluorescence from the µSPE 
















Figure 2.11 Fluorescence image of the μ-SPE surface when excited at 488 nm (300 ms 
exposure time) following DTT release of the biotinylated membrane proteins.  
 
We further verified that the selected proteins were indeed released from the affinity 
bed by measuring the fluorescence of the resulting effluent that was collected during the DTT 
infusion/rinse. Figure 2.12 shows a calibration plot of the fluorescence signal that was 
generated by the avidin-FITC (in DTT).  
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Figure 2.12 Calibration curve of varying concentrations of avidin-FITC. 
 The fluorescence signal from the effluent not only indicated that there were membrane 
proteins released from the µSPE bed. A sample of biotinylated MCF-7 membrane proteins 
that had been labeled with avidin-FITC was also measured in a fluorimeter so that we could 
determine the initial amount of membrane protein material being used. The concentration of 
biotinylated protein in a 1 mL sample was found to be 1.71 ± 0.25 pmol.  We ran MCF-7 
whole cell lysate (5 x 10
6 
cells) volumes of 500, 100, 50, 10, 5, and 1 µL, respectively through 
the µSPE bed. Recovery of biotinylated protein was calculated by examining the mass of the 
protein sample before and after purification on the µSPE device. For a 0.374 ± 0.03 pmol 
sample of biotinylated membrane protein input, a capture efficiency of biotinylated membrane 
proteins was estimated to be 34.92 ± 3.27%, while it increased to 83 ± 2.14% when the 
membrane protein concentration was set below 0.019 ± 0.00051 pmol (Figure 2.13). 
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Figure 2.13 The recovery of biotinylated MCF-7 membrane proteins loaded onto the µSPE 
device using the extraction/purification assay. The total concentration (pmol) before and after 
µSPE purification was estimated from fluorescence data, which only measured proteins that 
were biotinylated. Error bars in the graph represent standard deviations from three replicate 
runs. 
 
The lower recoveries that are observed with higher concentrations of biotinylated 
protein suggest that the amount of protein that was introduced exceeded the load capacity of 
the µSPE capture bed (i.e. available NeutrAvidin sites). The protein saturation point of 1.71 




2.3.3 Western Blotting Analysis to Evaluate the Purity of Extracted MCF-7 Membrane 
Proteins 
 
 To determine the purity of the µSPE fractions free from cytosolic contamination, 
Western blotting was performed using actin as a marker for cytosolic contamination because 
it is highly abundant in the cytosol. Western blotting using EpCAM (epithelial cell adhesion 
molecule) was also used to check for the presence of membrane proteins in µSPE effluent 
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The results for the actin Western blot of the protein fractions extracted using the 
detergent-based technique are shown in Figure 2.14. The Western blot clearly showed the 
presence of actin with intense bands in the total cell lysate (T) and the cytosolic (C) fractions. 
In addition, there was also an actin band in the lane where the membrane protein band was, 
suggesting contamination by cytosolic proteins using the detergent-based isolation technique. 
This indicated that the detergent-based method is not efficient in removing highly abundant 
cytosolic proteins from the membrane fraction. 
The same Western blot analysis was also carried out after processing the MCF-7 cell 
lysate (biotinylated) on the µSPE chip to check the purity of the membrane protein fraction. In 
this case, 25 ng of DTT-released biotinylated membrane protein was loaded onto the gel. 
Figure 2.14 B & C shows the blots of a biotinylated membrane protein sample that was eluted 
from the µSPE device. There is clear evidence of the actin band for the total lysate prior to 
processing using the µSPE device. Lane M of the actin Western blot consisted of the sample 
that was run through the µSPE affinity bed, subjected to DTT release with the effluent 
collected following release. In this case, no actin band was evident indicating that the 




Figure 2.14 (A) Actin Western blot of MCF-7 protein fractions that were extracted using a 
detergent-based extraction method (Section 2.2.4). The total lysate (T), membrane protein 
fraction (M), and the cytosolic protein fraction (C) were all analyzed. The blot shows that 
there is cytosolic protein contamination in the membrane protein fraction (presence of actin). 
(B) Actin Western blot of the µSPE extracted membrane proteins (M) and total cell lysate (T) 
(before on-chip analysis) and (C) EpCAM blot of total cell lysate and µSPE extracted 
membrane protein sample. The band indicates the presence of actin in the sample. The 
EpCAM blot confirms that there are membrane proteins present in the effluent from the SPE 
bed. 
 
We also ran an EpCAM Western blot to make sure that we did in fact have membrane 
proteins present in the µSPE/DTT release effluent. The blot confirmed the presence of 
EpCAM in the lane where the µSPE/DTT release effluent was loaded indicating that we were 
able to detect biotinylated membrane proteins using this Western blot procedure. 
2.3.4 Computational Modeling to Understand the Effects of the Chip Geometry on 
Protein Capture 
 
The µSPE bed consisted of a series of staggered microposts onto which NeutrAvidin 
was immobilized to serve as the material for enrichment and purification of the biotinylated 
membrane proteins introduced into the device via hydrodynamic flow. Within this section, we 
A C B 
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were interested in understanding how the µSPE bed’s geometry, in terms of micropost shape 
and spacing, affects the capture efficiency of proteins. These studies were carried out using 
computational fluid dynamics (CFD) conducted with COMSOL Multiphysics 4.3a as well as 
mathematical derivations using the principles of diffusion. 
2.3.4.1 CFD Modeling of Velocity Fields, Protein Flux, and Protein Capture in Several 
µSPE Bed Configurations 
  
For the CFD simulations, three model geometries composed of staggered rows of 
micropillars were tested: (I) Circular posts with radii of 50 µm and center-to-center spacing of 
150 µm; (II) circular posts with radii of 10.0 µm and center-to-center spacing of 40.0 µm; and 
(III) diamond posts with side length of 20.0 µm (fileted by 5 µm to reflect the fabrication 
limits of micro-milling) and center-to-center spacing of 40.0 µm. Geometries I and III were 
used to understand scaling effects (post size and post spacing), and geometry II was used to 
understand the effects of post shape (circular versus diamond). Note that in all of these model 
geometries, the number of posts was restricted to only a few staggered rows (relative to the 
hundreds occupying a physical µSPE bed) to ensure numerical tractability of the 
computations.  
Using these geometries, we conducted fluid dynamic simulations of steady-state (time 
independent) laminar flow through the µSPE beds. For this, COMSOL solves the Navier-
Stokes equations to provide velocity fields. For comparison, all µSPE beds were designed 
within COMSOL to have the same fluidic inlet with the fluid (modeled with the properties of 
water) entering the beds assigned a linear velocity of 0.83 mm s
-1
 to reflect a physical 
volumetric flow rate of 1 µL min
-1
. After solving for the steady-state velocity fields, the time-








and without adjusting for the effects of biotinylation) was 
calculated. 
We first simulated the steady-state (time independent) laminar flow profiles of water 
traveling through the µSPE beds. The CFD solutions for geometries I-III are shown in Figure 
2.15. It is clear that for all geometries, flow around the posts positioned nearest the bed walls 
is slightly reduced compared to the bulk flow likely resulting from viscous drag along the 
walls, an artifact of the Poiseuille flow, and the no-slip condition.  
 
Figure 2.15 Velocity profiles of SPE bed geometries 1-III. Flow fields are scaled in both size 
and magnitude. Solid, white arrows indicate the direction of flow.  
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It was also evident that the flow’s linear velocity is more homogenous throughout the 
µSPE beds for geometries II and III, an important point considering flow rate directly 
translates to protein mass flux. Thus, the beds with smaller posts may provide more uniform 
flow in addition to a higher surface area. Using these steady-state velocity fields, we 
conducted time-dependent simulations for the transport of a dilute protein (BSA) solution. 
These models were simulated for 17.5-25 s with a maximum time step of 0.01 s. 
Additionally, the BSA protein was permitted to react with the microposts through 
biotin-avidin binding. The reaction of a biotinylated protein (B) with immobilized avidin (A) 
is governed by: 
𝐴+𝐵↔𝐴𝐵      (1) 
where AB is the avidin-biotin-protein complex, i.e., the captured protein. The rate of this 
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The rate constants in Eq. (2) have been quantitated by surface plasmon resonance 











respectively. These parameters reflect the entropic considerations of surface reactions; they 
favor the reactant state more than free solution kinetics.
50
 Furthermore, we approximated the 
maximum surface density of extracted biotinylated membrane protein, [B]max, as 6.85 pmol 
cm
-2
. This is a one to one ratio with a theoretical monolayer of NeutrAvidin proteins and 
appropriately neglects the multivalency of avidin proteins due to steric effects between 
membrane proteins, which are of similar size to NeutrAvidin molecules.
51
  
These constants and the rate expression in Eq. (2) were used in conjunction with the 
velocity fields and time-dependent protein transport to provide the time-lapse images in 
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Figure 2.16A-D.  Line plots of the surface density of captured protein are also shown in 
Figure 2.16. This data indicates that for geometry I, less protein is initially captured on the 
rear surface area of the large, circular posts. However, this phenomenon is reduced after 
several seconds and the coverage of captured protein becomes more homogenous as it is for 
the other geometries. This is likely due to the reaction kinetics shown in Eq. (2).  
 
Figure 2.16 Time-dependent (with the first set of images arbitrarily assigned as 0 s) protein 
concentration profiles (A, rainbow scale), and surface densities of captured protein (B-D, grey 
scale along post borders) for SPE bed geometries III and I. Line plots of surface densities are 
presented for all three geometries against the spatial y-coordinate (illustrated in 0 s images). 
 
Only protein flowing in laminar flow streams passing directly over the post surface 
has the potential to be affinity captured. Initially, protein in these flow streams may be 
depleted by the front of the posts before they reach the rear surface area of the post. But, over 
time the higher surface density of affinity captured protein on the front of the posts disfavors 
protein capture by Eq. (2), leaving more protein for capture on the rear of the posts. This 
would likely not be visible on the smaller posts in geometry II and III. However, they too 
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exhibited reduced reaction kinetics at longer times in the line plots in Figure 2.16. Because 
biotinylated protein were infused over the course of an hour, it is not likely that heterogeneous 
protein immobilization on the posts of geometry I would be experimentally observable nor 
were they (see Figure 2.9) or bear any consequence on the µSPE bed’s performance for 
capturing biotinylated proteins from the whole cell lysate. 
2.3.4.2 Diffusion Model for Approximating the Effects of Post Geometry on the Effective 
Bed Length 
 
 Due to computational limits, COMSOL was incapable of modeling an entire µSPE 
bed, but it is wise to assess how protein diffusion propagates throughout the µSPE bed’s 
entire length (L = 24 mm). In general, diffusion of a protein is governed by Fick’s 2
nd
 law, 
where the probability (P) of occupying the axial position (x) at time (t) is dictated by its 
diffusion coefficient (D): 




   
   
                            (3) 
An analytic solution to this differential equation is: 
                    (   )  
 




   
)
                             (4) 
where P(x,t) is a Gaussian packet with standard deviation (  √    √     ̅ ), where  ̅ is 
the protein’s average velocity throughout the µSPE bed. The probability packet P(x,t) spreads 
in time, indicating that a protein molecule is more likely to occupy axial positions farther 
from its initial position.  
However, the protein does not travel linearly through the bed, instead it will travel 
around the posts and effectively travel a distance of         , where C is a geometric 
correction factor intimately tied to the post shape. For circular posts, the protein will travel 
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about a half perimeter of the circle yielding           ; for diamond posts, the protein 
travels about a triangle, yielding   √      ; these assignments can be shown to be 
independent of the post size and are geometrically illustrated in Figure 2.17. Consequently, 
the effective path length of proteins in an SPE bed with circular posts is roughly twice that of 
one with diamond posts permitting twice the time for diffusion to increase the probability that 
proteins interact with the posts. 
 
Figure 2.17 Schematic illustration of the path correction factor (C) for both circular and 
diamond posts. The probability of protein-post interaction (Pi) for geometries I and III, both 
with (solid black, where          √ ) and without (solid grey, where    ) the path 
correction factor applied to the µSPE bed’s length. 
 
If we consider a worst case scenario, where a protein has the initial position exactly 
centered (   ) between two posts with spacing   (boundary conditions of      ), we 
can approximate that after the protein has passed through the µSPE bed, the probability that it 
has diffused to and interacted with the posts (  ) is given by integration of the following 
equation: 
   (       ̅)   ∫  (         ̅
 
| |     
)         (5) 
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The standard statistical method (shown in Figure 2.18) to perform this integration uses 
z-scores associated with the Gaussian packet, where  ( )      and   ( ) is the normalized 
area of the Gaussian packet from -  to  ( ). Thus, Eq. (5) can be simplified to: 








]        (6)  
Figure 2.18 Schematic for extracting the probability of a protein interacting with SPE bed 
posts (Pi) from the Gaussian probability packets in the analytic solution of Fick’s 2
nd
 law. 
Equation (6) can then be solved with a standard Excel spreadsheet by calculating 
  √        ̅  then solving for  (   
 
 
) and    using the NORMSDIST function in a 
standard Excel worksheet. In Figure 2.18, we show the solutions for geometries I and III. 
Here, we used the average velocities through the µSPE beds I and III that were obtained via 
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the simulation results in Figure 2.15 and scaled these velocities proportionally for higher flow 
rates. Also, we tested both geometries for the effect of applying the path correction factors. 
Note that this model approximates the protein’s velocity as  ̅ irrespective of its axial position 
x, thereby ignoring Poiseuelle flow and under approximating diffusion effects. 
In all cases, higher flow rates restrict protein diffusion and increase the probability that 
proteins will never contact the microposts and thus, not be recovered. Regardless of the path 
correction factor, geometry III outperforms geometry I in this model, predominately because 
the smaller spacing between posts in geometry III necessitates the protein to diffuse a shorter 
distance to contact a post. If the path correction factor is not applied, geometry I has a 20% 
higher probability of capturing the protein flowing at 0.1 µL min,
-1 
and even with the path 
correction factor, which slightly enhances the performance of geometry I with respect to 
elongated protein path length for increased axial diffusion, geometry III remains optimal due 
to the small interpost spacing. In future developments of the µSPE geometry, circular posts 
with post spacing on the order of 10 µm (likened to geometry II) may enable increased 
throughput without detracting from the assay’s efficiency.  
2.4 Conclusion 
 A polymer microfluidic chip was designed, fabricated, and evaluated for the solid-
phase extraction and purification of membrane proteins from a cell lysate generated from 
MCF-7 cells that were subjected to a biotinylation step prior to lysis. The µSPE assay was 
shown to produce significantly lower levels of cytosolic protein contamination compared to a 
commercially-available detergent method, which is based on liquid-liquid extraction. 
Furthermore, the surface activation protocol via UV-exposure was simple in execution and the 
production of bed containing polymer micropillars formed via hot embossing did not require 
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extensive post-fabrication steps to create the selection bed, such as the addition of 
functionalized beads or the formation of chemically modified polymer or monolithic supports. 
We were able to recover ~83% of the biotinylated protein fraction using 100 µm diameter 
circular posts that were spaced by 50 µm. The total load of protein for this bed geometry was 
determined to be 6.85 pmol cm
-2
.  While the total load is modest, this can be increased by 
reducing the post diameter and spacing. 
The results secured using this novel µSPE device and assay for the extraction and 
purification of membrane proteins will provide a very attractive platform for future studies 
requiring the analysis of these proteins to determine potential therapeutic targets or selection 
agents for various cell types due to the higher purity fractions isolated and the ability to 
process small numbers of cells with high enrichment factors.  For example, when the µSPE 
device is integrated to devices for multidimensional electrophoresis, solid-phase proteolytic 
digestion and mass spectrometry, top-down proteomic analysis of membrane proteins from 
rare cells can be undertaken, such as circulating tumor cells. 
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A common method for protein analysis involves the use of two-dimensional electrophoresis 
that commonly employs an isoelectric focusing (IEF) dimension, which separates the proteins 
based upon differences in their isoelectric point (pI) using immobilized pH gradient strips 
(IPG), followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
which sorts proteins through differences in their molecular weights (Figure 3.1). To determine 
the identity of the various proteins comprising these 2D maps, the spots can be subjected to 
high resolution MS/MS analysis (top-down proteomics) or digested via proteolytic enzymes 
followed by MS analysis (bottom-up proteomics).
27
 Complex biological samples, such as 
blood serum and cell lysates, hold great promise for clinical diagnostics. The wide range of 
protein components that can potentially exist in complex biological samples makes it difficult 
to analyze these types of materials using one-dimensional (1D) separations due to the limited 
peak capacity provided by these separation platforms. 
As noted by Giddings,
2
 the combination of two different separation techniques can 
provide a significantly higher peak capacity, P, than the individual 1D mechanisms as long as 
the dimensions compromising the multi-dimensional separation are orthogonal, which means 
that the selected dimensions possess different, but compatible, separation mechanisms.  
Furthermore, the subsequent dimension in any multi-dimensional separation should not 
destroy the resolution achieved by the previous one. If the separation mechanisms of the 
multi-dimensional separation are orthogonal, the product of the peak capacity contained 
within the individual separation dimensions gives the number of resolved components.
3
 
Although IEF/SDS-PAGE continues to be the main separation method for many proteomic 
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studies, there are still drawbacks associated with utilizing the technique. IEF/SDS-PAGE is a 
time-consuming and laborious process involving extensive gel pouring and pH gradient 
formation as well as long operational times (>24 h) to generate the required 2D map. 
Moreover, after the separation, protein bands require staining for visualization and subsequent 
band excision from the gel for follow-up identification purposes, which can result in sample 
loss.
4,5
 In addition, membrane proteins tend to be excluded when using IEF/SDS-PAGE due 
to their poor solubility in the buffering system utilized,
6,7
 and the staining and visualization 
techniques associated with IEF/SDS-PAGE often do not detect proteins that are typically low 
in abundance due to limitations in the mass detection limits.
8
 




Because of the drawbacks of 2D IEF/SDS-PAGE, researchers focused their efforts 
toward the use of capillary-based 2D separations using various combinations of 
electrophoresis or chromatography methods. Examples of these types of 2D platforms include 
capillary sieving electrophoresis coupled to micellar electrokinetic capillary 
chromatography,
9-11
 nano-reverse phase liquid chromatography coupled to strong cation 
exchange chromatography,
12
 and size-exclusion liquid chromatography coupled to reverse 
phase liquid chromatography
13
 have all been used for the analysis of proteins by researchers.  
While capillary-based multi-dimensional separation reports have shown success in 
eliminating tedious tasks such as gel pouring and reducing the development time of 
electrophoresis, the increasing demands on proteomic studies have compelled the need to 
further reduce development times, process smaller sample volumes, generate higher 
throughput by performing multiple separations in parallel, and integrate front-end processing 
to the 2D separation. Therefore, the techniques encompassing microchip capillary 
electrophoresis (µ-CE) have been considered as attractive alternatives to their traditional 
capillary counterparts. 
3.1.1 2D Separations on Microfluidic Chips 
Microchip 2D separations offer automation capabilities and rapid separations with 
high resolving power as opposed to the conventional slab gel techniques (IEF/SDS-PAGE). 
They can also provide viable interfaces between the separation dimensions to minimize 
unswept volumes between separation dimensions preserving plate numbers. The separation 
efficiencies are high in µ-CE due to effective heat dissipation, the ability to use higher electric 
field strengths, minimal sample consumption due to smaller footprints, and faster times 
because of shorter column lengths. Li et al.
14
 integrated IEF with parallel sodium dodecyl 
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sulfate micro-capillary gel electrophoresis (SDS µ-CGE) for a comprehensive 2D separation 
of  five model proteins and generated a peak capacity of ~1,700 in 10 min. Chen et al.
15
 
described a microfabricated 2D IEF/SDS-PAGE system that separated three model proteins a 
little under 2 min.; however, the peak capacity was not reported. Yang and collaborators
16
 
reported a 2D IEF/SDS-PAGE separation of whole cell E. coli protein lysate with an 
estimated peak capacity of 2,880 that was obtained within 12 min. 
All of the abovementioned examples of microchip 2D employed IEF in the first 
dimension. Regrettably, IEF requires an equilibration step before the focusing step,
16
 which in 
turn increases the overall development times of the entire 2D separation. Additionally, IEF is 
not compatible with highly hydrophobic proteins (membrane proteins) as they are not 
compatible with the aqueous buffers required for IEF. To avoid some of the issues associated 
with using IEF, alternative techniques such as CZE or micellar electrokinetic chromatography 
(MEKC) have been employed.  
Ramsey and co-workers
17
 separated peptides with a 2D microchip system that 
combined open-channel electrochromatography (OCEC) with CZE in which they reported a 
peak capacity of 150 that was obtained in 13 min. The same group also utilized glass 
microfluidic devices to perform 2D separations of bovine serum albumin tryptic digest.
18
 A 
MEKC separation was performed in 19.6 cm-long serpentine channel with the peptides 
rapidly sampled into a 1.3 cm long second dimension channel where they were separated by 
CE. Figure 3.2 shows the device employed for the separations. The turns in the serpentine 
channels were asymmetrically tapered to minimize geometrical contributions to band 




Figure 3.2 Image of the microchip used by Ramsey et al. Injections were made at valve 1 
(V1) for the first dimension MEKC separation and at valve 2 (V2) for the second dimension 
CE separation. Detection of the sample was done at 1 cm downstream from V2 at point D 
using laser-induced fluorescence. The reservoirs are labeled sample (S), buffer 1 (B1), sample 
waste 1 (SW1), buffer 2 (B2), sample waste 2 (SW2), and waste (W). (Reproduced from 
Ramsey, J. D.; Jacobson, S. C.; Culbertson, C. T.; Ramsey, J. M. Anal Chem 2003, 75, 
3758.
18
 with permission, Copyright 2013, American Chemical Society). 
 
The electric field strengths were 200 V/cm for MEKC and 2,400 V/cm for CE. A peak 
capacity of 4,200 (110 in the first dimension and 38 in the second dimension) was reported for 
the 2D separation of bovine serum albumin tryptic digest with an analysis time of less than 15 
min. 
 The use of microemulsions in microemulsion electrokinetic chromatography 
(MEEKC) has also emerged as an attractive alternative to MEKC. It was first introduced by 
Watarai et al.
19
 in 1991 for the separation of fluorescent aromatic compounds and has been 
widely applied for the separation of various analytes including proteins.
20-23
 The separation 
medium in MEEKC is a microemulsion, which is a transparent solution consisting of an oil 
(i.e., n-heptane), a surfactant (i.e., SDS), a co-surfactant (i.e., n-butanol), and water. The 
structure of oil in a water emulsion is similar to that of micelles in MEKC except the 







Figure 3.3 (A) Depiction of micelle formation in aqueous buffer and its utilization in the 
second dimensional phase have a microchip 2D SDS µ-CGE and MEKC protein separation. 
(B) Depiction of microemulsion formation in aqueous buffer and its utilization in the second 
dimensional phase of a microchip 2D SDS µ-CGE and MEEKC protein separation. a = 
anionic proteins acquire their charge in two ways: (1) because the pH conditions for the 
separation is above their pKa and (2) because SDS imparts a negative charge on the proteins 
during sample prep and during the first dimension separation. (Reproduced from Osiri, J. K.; 
Shadpour, H.; Soper, S. A. Anal Bioanal Chem 2010, 398, 489 with permission, Copyright 
2013, Springer Science and Business Media). 
 
Figure 3.3 depicts the formation of micelles in aqueous buffer, its employment in the 
second dimensional phase of 2D SDS µ-CGE and MEKC protein separation, and how 
microemulsions are formed. The SDS micelles form in buffer above the SDS cmc, critical 
micellar concentration (0.24% w/v). The aggregate number for SDS is about 62 molecules 
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forming a core diameter of ~17Å. In a reverse polarity mode (detection is anodic), SDS 
micelles migrate towards the anode due to their ionized sulfate group, which is negatively 
charged, whereas the direction of EOF is towards the cathode. Separation in the MEKC is 
based on the differences in the partition coefficient of proteins within the micelles and the 
aqueous phase and according to the mass-to-charge ratio of proteins when they are in the 
aqueous medium. 
More hydrophobic domains within a protein result in stronger hydrophobic character 
and the more hydrophobic proteins have a tendency to interact more with the micellar core. 
On the other hand, anionic proteins experience columbic repulsion and may not interact with 
the micelles. This is especially true when their hydrophobic domains are masked by SDS (see 
rods that are gold only or gold/blue without any black color). These proteins are separated 
based on their electrophoretic mobility in the aqueous medium with the proteins possessing 
the highest charge-to-mass ratio migrating the fastest. 
Overall, the migration of proteins is in the order of 1-6 with protein 1 migrating the 
fastest and protein 6 migrating the slowest. In MEEKC, SDS surfactants impart a net negative 
charge to the oil emulsions, and the co-surfactant (n-butanol) reduces the surface tension 
between the oil and the aqueous phase, which results in a miscible oil/water system. The 
hydrophobic core diameter for the microemulsion is ~100Å. 
3.1.2 Previously Reported Work Employing SDS µ-CGE with MEKC for 2D 
Separations 
 
 The Soper research group has reported 2D microchip separations using SDS µ-CGE 
with both MEKC and MEEKC. In 2006, Shadpour and Soper described two-dimensional 
electrophoretic separations of proteins in a PMMA-based microchip. SDS µ-CGE (SDS 14-
200 sieving matrix with 12 mM Tris-HCl, 0.1% w/v (3.5 mM) SDS, pH 8.5, containing 
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0.05% MHEC, methyl hydroxyl ethyl cellulose) and MEKC (12 mM Tris-HCl, 0.4 % w/v (14 
mM) SDS, pH 8.5, containing 0.05% MHEC) were used as the separation modes in the first 
and second dimension of the electrophoresis, respectively. The use of MHEC aids in the 
suppression of the electroosmotic flow (EOF) while preserving the selectivity of the 
separation. The electrophoretic separations were carried out at ambient temperature in reverse 









Figure 3.4 Photograph of the PMMA µ-capillary electrophoresis chip used for the 2D 
separations. The channel width in all cases was 15 µm with a channel depth of ~30 µm. The 
solution reservoirs were; (A) sample reservoir; (B) sample waste reservoir; (C) SDS µ-CGE 
buffer reservoir; (D) SDS µ-CGE buffer waste reservoir; (E) MEKC or MEEKC buffer 
reservoir; (F) MEKC or MEEKC buffer waste reservoir. d1 represents the LIF detection 
position for the 2D separations. (Reproduced from Shadpour, H.; Soper, S. A. Anal Chem 
2006, 78, 3519.
24
 with permission, Copyright 2013, American Chemical Society). 
 
The PMMA microchip (Figure 3.4) incorporated a 30-mm SDS µ-CGE and a 10-mm 
MEKC dimension length and electrokinetic injection and separation were used with field 
strengths of up to 400 V/cm. Platinum wires were used to apply high voltages to the 
reservoirs. For the SDS µ-CGE dimension, the injection and effective separation lengths were 
each 10 mm. The total separation channel length for a complete 2D separation was 20 mm 




 dimensions). The 30 nM protein mixture consisted of 10 
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Alexa Fluor 633 conjugated proteins (wheat germ agglutinin (WG), actin (AC), ovalbumin 
(OV), protein A (PA), streptavidin (ST), bovine serum albumin (BSA), Helix pomatia (HPA), 
transferrin (TR), concanavalin A (CO), and lectin peanut agglutinin (PNA), ranging in size 
from 38 to 110 kDa, detected using laser-induced fluorescence with excitation/emission at 
633/652 nm.  They reported plate numbers (N) of 4.8 x 10
4 
and 1.2 x 10
4 
in the SDS µ-CGE 
and MEKC separation dimensions, respectively, for the proteins corresponding to plate 
heights (H) of 0.62 and 0.87 µm. 
Both the SDS µ -CGE (1D separation) and MEKC (1D separation) are shown in 
Figure 3.5. The electropherograms suggest that the proteins that are closer in MW comigrate 
and are not resolved from one another indicating the need for a 2D separation that can provide 
improved resolution. The time to start the second dimension (MEKC) depends on the 
migration time (MT) of the smallest protein or co-migrated proteins in the SDS µ-CGE 
dimension. The migration time can be estimated by using Eq 1. for the smallest component 
(lowest MW) in any given mixture. For this work, the estimated MT was ~71 s for WG, 
which was the smallest protein (38,000 Da) in the mixture. Therefore, the first MEKC cycle 
was set to start at 70 s.  
 
log (MW) = 1.59 x 10
-2
MT + 3.45 (1) 
 
The MEKC cycles were performed by proper switching of the high voltage applied to 
points E and F (see Figure 3.4). The word “cycle” refers to a complete MEKC electrophoretic 
run that was used for the second dimension. 
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Figure 3.5  (A) SDS µ-CGE analysis (1D separation of a 30 nM protein mixture using the 
PMMA microchip. (B) The MEKC separation (1D) of a 30 nM protein mixture using the 
PMMA microchip. (Reproduced from Shadpour, H.; Soper, S. A. Anal Chem 2006, 78, 
3519.
24
 with permission, Copyright 2013, American Chemical Society). 
 
Based on all proteins eluting from the MEKC channel within a 10 s separation 
window, the MEKC cycles were then fixed at 10 s. For different protein mixtures, longer 
separation windows could be selected at the expense of longer 2D development times. The 




separation are shown in Figure 3.6. It can be seen that the 2D analysis was able to resolve all 
10 proteins in the mixture, including those species that could not be separated using individual 
1D separations under similar experimental conditions. 
 
Figure 3.6 2D µ-CE separation of a 30 nM protein mixture in the PMMA microchip. (A) 
Linear output of the LIF 632.8 nm detector system from the 2D analysis of the protein sample 
(B) A three-dimensional image of the data shown in A with the cycle number plotted versus 
the MEKC migration time. (Reproduced from Shadpour, H.; Soper, S. A. Anal Chem 2006, 
78, 3519.
24
 with permission, Copyright 2013, American Chemical Society). 
 
 For some time, most of the µ-CE examples were focused on demonstrating proof-of-
concept of the multidimensional separation using model systems, which can limit the number 
of components analyzed with the constituents present in similar concentrations, both of which 
do not represent “true” biological samples. Therefore, Osiri and co-workers
25
 also reported 
2D profiling of fetal calf serum (FCS) proteins within 30 min using SDS µ-CGE in the first 
dimension and µ-MEKC in the second dimension. The FCS proteins were covalently labeled 
with a thiol-reactive AlexaFluor 633 dye prior to the µ-CE 2D separation and detected using 
laser-induced fluorescence (LIF). The sample was electrokinetically injected into the 
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separation channel at 200 V/cm with the 2D SDS µ-CGE × MEKC separations in the first and 
second dimensions performed at 300 V/cm and 400 V/cm respectively.  
Figure 3.7 SDS µ-CGE/µ-MEKC 2D separation of a FCS protein mixture. The 2D SDS µ-
CGE × MEKC were performed at 300 V/cm and 400 V/cm, respectively. (A) 2D image of the 
microchip FCS map. (B) 3D landscape of the FCS proteins. Reproduced from Osiri, J. K.; 
Shadpour, H.; Park, S.; Snowden, B. C.; Chen, Z. Y.; Soper, S. A. Electrophoresis 2008, 29, 
4984.
25
 with permission, Copyright 2013, John Wiley & Sons).  
 
The SDS µ-CGE was performed utilizing an effective length, the length used for the 
separation, Leff = 60 mm while the µ-MEKC separation employed Leff = 50 mm. The results 
of the 2D separation are shown in Figure 3.7. The authors reported a peak capacity for the 2D 
separation of 2,600 (±149). 
Separations on microfluidic platforms have garnered much appeal for the analysis of 
complex biological samples because they can easily lend themselves to performance 
characteristics that rival their macroscale counterparts using a much shorter operational time, 
but still generating much improved data production rates. In addition, these formats, due to 
B A 
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their small footprint and lithographic fabrication techniques, will permit the development of 
multi-channel formats that can significantly improve the production rate of data. In the 
aforementioned report, our lab has demonstrated the ability to generate peak capacities of 
2,600 (±149) for a biological serum sample using an 11 cm effective separation length in both 
dimensions. Although the peak capacity is well below the number of protein components 
typically found in a serum proteome, it is still attractive for the analysis of a complex sample 
such as serum. In addition, the isolation of sub-populations of protein types, such as 
membrane proteins, is also appealing for this peak capacity and the analysis of a sample of 
cell lysate.  
Therefore, in this work, we report the use of a polymer-based microchip for 2D 
profiling of the membrane protein fraction of MCF-7 cell lysates with sufficient peak 
capacities using SDS µ-CGE in the first dimension and µ-MEKC in the second dimension. 
The readout strategy relied upon the employment of laser-induced fluorescence (LIF), which 
was accomplished by covalently labeling the MCF-7 membrane proteins with an amine-
reactive DyLight NHS Ester 550 dye prior to the µ-CE 2D separation. The SDS µ-CGE was 
performed using Leff = 30 mm while the µ-MEKC separation utilized Leff = 40 mm. We then 
compared our µ-CE separation results with results reported in literature on the conventional 
2D IEF/SDS-PAGE of MCF-7 cell lysate. 
3.2 Materials and Methods 
3.2.1 Microchip Fabrication 
PMMA was selected as the µ-CE substrate because of its suitable physiochemical 
properties for this application, such as minimal non-specific adsorption artifacts and low 
levels of autofluorescence, improving the detection limits for ultra-sensitive fluorescence 
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detection. Microchips were made according to procedures described previously. In brief, 
microstructures were micromilled into a brass plate (0.25” thick alloy 353 engravers brass, 
McMaster-Carr, Atlanta, GA, USA) using a Kern MMP 2522 micromilling machine (KERN 
Mikro-und Feinwerktechnik GmbH & Co., Germany).  
Once fabricated, the mold master produced PMMA replicates using hot-embossing. 
Hot-embossing required heating the molding tool to 155°C  and pressed into the PMMA plate 
with a pressure of 1,100 psi for 4 min using a PHI Precision Press (PHI-Tulip, City of 
Industry, CA, USA). Following embossing, the PMMA substrate was cooled to room 
temperature and removed from the molding die. The embossed PMMA substrate was cleaned 
with 50% isopropanol in ultrapure water.  Finally, a PMMA cover plate (0.250 mm) was 
thermal fusion bonded to the substrate by heating in a temperature programmable furnace to 
107°C, slightly above the Tg of PMMA. Figure 3.8A shows the topographical layout of the 
microdevice used for this work. All channels were 50 µm deep and 50 µm wide. Buffer, 
sample, or waste reservoirs are shown in Figure 3.8A, in which letters A to F are 
representative of the 1.5 mm diameter solution reservoirs on the PMMA microchip. 
3.2.2 Laser-induced Fluorescence (LIF) Detection, Power Supply and Data Analysis 
 Fluorescence detection was accomplished using an in-house constructed LIF system.  
A schematic diagram of this detection system is shown in Figure 3.8B. The excitation source 
consisted of a laser diode with a lasing wavelength of 532 nm (LBS-532-TD-5, Laserglow 
Technologies, Toronto, ON, Canada). The diode laser light was filtered using a laser line filter 





Figure 3.8 (A) Schematic of the 2D microchip electrophoresis device used for these studies. 





channels were 4 cm (filled with gel media) and 5 cm (filled with MEKC buffer), respectively, 





dimensions were 3 cm and 4 cm, respectively. (B) Diagram of the in-house constructed LIF 
system used for the µ-CE separation. The system was configured in an epi-illumination 
format and was equipped with a 40x microscope objective (NA = 0.65) used to focus the laser 
excitation radiation into the micro-separation channel and collect the resulting fluorescence as 
well (epi-illumination). An x-y-z micro-translational was used to position the chip above the 
objective. A 532 nm diode laser served as the excitation source. 
 
A dichroic mirror (XF2018, Omega Optical) reflected the 532 nm and the laser light 
beam was directed into a focusing objective using a second dichroic mirror (XF2055, Omega 
Optical). The excitation beam was focused utilizing a 40x microscope objective (Nikon, 
Natick, MA, USA) into the separation channel of the microchip, which was situated on an x, 
y, z micro-translational stage (Newport, Irvine, CA, USA). The fluorescence emission 
resulting from the DyLight 550 labeled membrane proteins was collected by the same 
objective and transmitted through the dichroic, reflected onto another dichroic mirror 
(DMLP605, Thorlabs, Newton, NJ, USA) and finally filtered through a filter stack containing 
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a long pass filter (CWL = 550 nm, 3RD550LP, Omega Optical) and a band pass filter (CWL 
= 570 nm, XB99, Omega Optical).  
The resulting photons were transduced employing a single photon avalanche diode 
(SPAD; SPCM 200B, PicoQuant, Berlin, Germany). Programmed high-voltage was applied to 
the reservoirs of the microchip with six independently controlled power supplies (EMCO, 
Sutter Creek, CA, USA). Electrical contact between the solution in the fluid reservoirs and the 
high-voltage leads was achieved utilizing platinum wires (Scientific Instrument Services, 
Ringoes, NJ, USA). The LIF signals were acquired on a personal computer equipped with an 
I/O interface board (CB-68LP, National Instruments, Austin, TX, USA) and a pulse converter 
(TB-01, IBH, Glasgow, UK). The software for data acquisition and control of the power 
supply was created using LabView. The LabView program interface is shown in Figure 3.9. 
Dye-labeled protein samples were first electrokinetically injected into the injection cross (A-
B, Figure 3.8A) by applying a positive potential at waste reservoir (B) while grounding the 
sample reservoir (A). Data were collected continuously from the start of the initial SDS µ-
CGE after the injection step. SDS µ-CGE was initiated by applying a positive potential at the 
waste reservoir (D) and grounding reservoir C. 
 In this particular case, proteins were sampled into the second dimension from the 
onset of the first dimension; therefore, proteins were allowed to separate in the second 
dimension after a 3 s electrophoretic run in the first dimension by applying a positive potential 
to reservoir E while grounding D. This 3 s separation in the first dimension transferred 
proteins into the second dimension for further separation. LIF was monitored on E-F at 40 
mm (d, see Figure 3.8A) from the intersection of C-D and E-F (see Figure 3.8A). 
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Figure 3.9 Computer screen-shot of the LabView program used to control the power supply 
that applies voltage to the reservoirs during the electrophoretic separations of the MCF-7 
membrane proteins. The total separation time and the time to start the sampling into the 
second dimension is also set using this program. 
 
Raw 2D electropherograms were converted to 2D images and then to three-
dimensional (3D) landscape representations (see Results and Discussion) by taking the LIF 
signals from successive runs for each MEKC cycle and plotting the electropherogram at the 
corresponding cycle on the SDS µ-CGE axis. This procedure was performed using OriginLab 
software (Northampton, MA, USA) and ImageJ software (National Institutes of Health, 
Bethesda, MD).  
3.2.3 Fluorescence Labeling of the MCF-7 Membrane Protein Fraction 
 Prior to fluorescence labeling and separation, the MCF-7 membrane proteins were 
extracted as described previously in Section 2.2.4 using the Mem-PER™ Plus Membrane 
Protein Extraction Reagent Kit available through Pierce Biotechnology (Rockford, IL). The 
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membrane proteins were covalently labeled with DyLight 550 (excitation/emission = 562/576 
nm), an amine-reactive dye (Pierce Biotechnology, Rockford, IL, USA) following the 
manufacturer’s guidelines. Briefly, after extraction, the membrane proteins were reacted with 
the DyLight 550 in an approximate 1:10 molar ratio for 1 h. The excess dye was removed 
using a Zeba Spin column (Pierce Biotechnology, Rockford, IL, USA). The amine reactive 
dye contained N-hydroxysuccinimide (NHS) esters that reacted with primary amines on the 
membrane proteins, forming a stable, covalent amide bond. The DyLight 550-conjugated 
proteins of the membrane protein fraction were then diluted in the µ-CE run buffer in a 1:5 
volume ratio (membrane protein sample: run buffer) along with 2-mercaptoethanol and heated 
to 95°C for 5 min. Prior to use in the microchip, all solutions were filtered with a 0.2 µm 
Nylon-66 membrane syringe filter (Cole-Parmer Instrument Co., Vernon Hills, IL, USA) 
except for membrane protein solutions, which were centrifuged (~6,000 rpm, 5 min) to 
remove any particulates. 
3.2.4 2D Electrophoretic Separations with 2D SDS-PAGE/MEKC Microfluidic Device 
 Before the electrophoretic separation, a solution of 2 mg/mL of methyl hydroxyethyl 
cellulose (MHEC) (Fluka BioChemika, Switzerland) was dissolved in 1X PBS (pH = 7.2, 
Sigma-Aldrich, St. Louis, MO, USA) and flushed through the fluidic channels through 
reservoir A (see Figure 3.8A) while applying vacuum to reservoir F. This process aids in the 
suppression of the electroosmotic flow (EOF). The EOF in PMMA channels with buffer 







 It should also be noted that no sieving properties are provided by 
buffers containing methylcellulose derivatives (e.g., MHEC) when the concentration is below 
0.1%.
311
 All electrophoretic separations were carried out at ambient temperature in reverse 
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mode (detection end anodic) for both SDS µ-CGE and the MEKC dimensions. Prior to the µ-
CE 2D separation, the first dimension channel (see Figure 3.8A) was filled with a sieving 
matrix, which consisted of SDS 14-200 linear polyacrylamide gel (Beckman Coulter Inc., 
Fullerton, CA, USA) containing 0.05% w/v MHEC. The gel filling was monitored using 





 dimensions. The second dimension channel was then filled with the MEKC buffer, which 
consisted of 12 mM Tris-HCl, 0.4% w/v SDS, and 0.05% w/v MHEC (pH = 8.5). 
For the injection/separation scheme, shown in Figure 3.10, 2D separations were 
performed in channels A-B, C-D, and E-F serving as injection, 1
st
 dimension SDS µ-CGE and 
2
nd
 dimension MEKC channels, respectively, and setting the detection point at d (see Figure 
3.8A). After the gel and run buffers were pressure filled into the channels, reservoir A was 
emptied and subsequently filled with 2 µL of the dye-labeled membrane protein sample. The 
sample was injected into the sampling channel (see A-B channel, Figure 3.8A) at 200 V/cm. 
The injection was initiated by grounding the voltage to the sample reservoir (A, Figure 3.8A) 
and applying +0.30 kV to the waste reservoir (B, Figure 3.8A) to fill the cross channel (points 
C-F were floated during the injection). 
Following injection, a high positive voltage was switched to point D and point C was 
grounded (Figure 3.8A). Then, pull back voltages (~10% of applied voltage to point D) were 
applied to the sample and waste reservoirs (A and B, see Figure 3.8A). The electric fields (E) 








Figure 3.10 The injection/separation scheme depicting the formation of the protein plug when 
voltages are applied during injection and separation, respectively. 
 
Table 3.1 represents the high-voltage protocol adopted for the 2D separation.  As 
shown in this Table, the injection and run steps were the same as discussed previously. The 
SDS µ-CGE separation was carried out at 350 V/cm using Leff = 30 mm (see C-D channel, 
Figure 3.8A). The 2
nd
 dimension MEKC separations were programmed to begin after a 30 
min electrophoretic run time in the 1
st
 dimension (SDS µ-CGE). Each 2
nd
 dimension MEKC 
cycle consisted of a 250 s run cycle (MEKC development time) and operated at a field 
strength of 400 V/cm, which was found to be sufficient time to assure that all of the 
components injected into the 2
nd








Table 3.1. High-voltage protocol for 2D separations using the PMMA microchip. Letters A – 
F refer to reservoirs on the 2D platform as shown in Figure 3.7A. 
1
G: Grounded, F: Floating. 
 
Sample eluting from the 1
st
 dimension was injected into the 2
nd
 dimension after a 3 s 
run period in the 1
st
 dimension. During the MEKC cycle, the applied field in the 1
st
 dimension 
was stopped, parking the components in the 1
st
 dimension during the 2
nd
 dimension run. 
 3.2.5 2D Slab Gel Separation of MCF-7 Proteins Using IEF/SDS-PAGE  
The results of the traditional 2D gel electrophoresis from the work of Pionneau and 
co-workers
27,28
 was used as a comparison of traditional 2DE gel separations of MCF-7 
proteins utilizing IEF with SDS-PAGE. IPG strips from pH 5 to 8 were used in the first 
dimension. The strips were rehydrated with 150 µg of protein until a total of 195,000 V/h was 
reached. After focusing, the strips were then placed on 18 cm x 20 cm x 1 mm 8–18.5% 
polyacrylamide linear gradient gel for the separation in the second dimension. SDS-PAGE 
was carried out at 40 V for 1 h, and 100 V for 21 h and stained with silver nitrate for 
visualization.  
3.2.6 Software Analysis of 2D Data 
 In order to obtain a 3D image of the electrophoretic data from the microchip, a text file 
of the raw 2D run formatted into a 3D matrix was input into OriginLab (Northampton, MA, 




Step A B C D E F 
Injection G + 0.30 F F F F 
SDS µ-CGE + 0.14 + 0.14 G + 1.40 F F 
Second 
MEKC cycle 
+ 0.14 + 0.14 F F G + 2.00 
First to second 
sample 
transfer 
+ 0.14 + 0.14 G + 1.40 F F 
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matrix was then plotted as a 3D surface plot. A 2D image plot was also done in ImageJ 
(National Institutes of Health, Bethesda, MD) to resemble a 2D gel. 
3.3 Results and Discussion 
3.3.1 Results of 2D Slab Gel Separation of MCF-7 Membrane Proteins Using IEF/SDS-
PAGE 
 
As it is shown in Figure 3.11, the whole cell extract gel has many more protein spots, 

















Figure 3.11 2D protein patterns from MCF-7 cell membrane extract and whole-cell extract. 
The 150 µg of protein was separated first on the IPG strips and then on an 8-18.5% gradient 
gel followed by silver staining. (Reproduced from Pionneau, C., Canelle, L., Bousquet, J., 
Hardouin, J., Bigeard, J., Caron, M., Joubert-Caron, R. Cancer Genomics & Proteomics 2005, 
2, 199 with permission, Copyright 2013). 
 
This confirms that it is highly possible that some membrane proteins could have been 
missed and/or not separated because they never entered the gel from the IPG strips because 
the proteins are hydrophobic and the buffers are aqueous (hydrophilic).  There is also more 
band smearing in the membrane protein gel as opposed to the whole cell extract that could 
also be due to the native characteristics of the hydrophobic membrane proteins and their 
insolubility, post-translational modifications, and/or nucleic acid contamination. The average 
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spot size was determined to be ~200 (±4.6) pixel
2
, a peak area of 117,924 pixel
2
, and a peak 
capacity of 589 (±5.1) pixel
2
. 
3.3.2 1D µ-CGE of MCF-7 Membrane Protein Fraction Employing SDS-PAGE 
The use of a highly viscous gel can alter a separation to become a size-based 
separation, minimize the diffusion of solutes, prevent analyte adsorption onto the microchip 
walls, and aid in EOF suppression.
29
 Separating proteins in their native state (non-denatured) 
can result in band smears, poor migration time, poor reproducibility, and less distinct protein 
spots.
30
 In addition, the electrophoretic mobilities of native proteins are dependent upon the 
mass-to-charge ratios rather than their molecular weight solely;
31
 therefore, the formation of 
SDS-protein complexes after denaturing establishes the foundation for performing 
electrokinetic protein transfer due to the overall negative charge of the proteins but also 
prepares the proteins for a size-based separation.
14
  
We were interested in analyzing the peak capacity for a 1D µ-CGE separation of the 
MCF-7 membrane proteins using Leff = 30 mm with SDS as the denaturing and complexing 
agent and polyacrylamide gel electrophoresis sizing matrix. The results of the SDS µ-CGE 
analysis using the PMMA microchip are shown in Figure 3.12. As seen in the 
electropherogram, approximately 22 bands could be observed with varying degrees of 
resolution and widths due to potential peak overlap arising from proteins with similar 
molecular weights. From the data, (see bands marked with an asterisk in Figure 3.12), we 
determined the average peak width was estimated to be 3.1 ±2.3 s, producing a plate number 
of 4.8 x 10
5 
±1.6. From these values and a separation window of ~25 min (defined by the 
migration time difference between the last and first migrating components), we estimated a 
peak capacity for the 1D separation to be 55 ±3.3 (n = 3). 
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Figure 3.12 SDS µ-CGE 1D separation of MCF-7 membrane proteins from whole cell lysate. 
The protein sample, which was labeled with an amine-reactive fluorescent dye, DyLight 550, 
was placed into reservoir A of the microchip (see Figure 3.7A) and electrokinetically injected 
into the separation channel at 200 V/cm. The 1D SDS µ-CGE was performed at E = 350 
V/cm. The total separation length was 4 cm with an effective length of 3 cm. 
 
Obviously, this is well below the level necessary to analyze a sample as complex as 
that projected for a mammalian proteome. The average peak width determined above from the 
SDS-PAGE dimension was then used to select the appropriate sampling time into the second 
dimension, which was set at 3 s. 
3.3.3 2D µ-SDS-PAGE/ µ-MEKC Separation of MCF-7 Membrane Proteins 
 In the 2D electrophoretic separation, SDS-PAGE was used as the first dimension and 
MEKC as the second dimension. SDS forms complexes with proteins, which are subsequently 
electrophoresed through a sieving matrix allowing for the separation of species primarily 
based on differences in the molecular weights. MEKC utilizes micelles as a pseudo-stationary 
phase with separation based upon selective partitioning of solutes to the micelles. In the case 
here, we are employing SDS micelles as a pseudo-stationary phase, which provides an 




 from our group has previously demonstrated the orthogonality of SDS-MEKC to SDS µ-
CGE, making it an elegant format for producing high peak capacities for multi-dimensional 
electrophoretic analysis of intact proteins. Using the migration order and migration times of 
10 model proteins, the degree of orthogonality was evaluated and a plot of the normalized 
migration time for a SDS-PAGE 1D separation versus that of the SDS MEKC 1D separation 
produced a scatter plot with minimal data points occurring along the diagonal (slope = 1.0, 
intercept = 0.0) providing an orthogonality value between the two separation mechanisms of 
77%. 
 In the 2D format utilized for this work, electrophoretic zones are “parked” in the first 
dimension while the second dimension is affected in a serial fashion. Therefore, issues with 
zonal dispersion due to longitudinal diffusion should be considered because it can have a 
significant impact on the peak capacity of the separation for the 2D analysis. This was 
achieved by calculating the height equivalent to a theoretical plate for longitudinal diffusion 
only (HD) of the 1D SDS µ-CGE dimension and comparing that value to HTOT secured from 
the complete 2D separation. A representative diffusion coefficient for proteins in a sieving 






, which is the measured diffusion coefficient 
of cytochrome C in polyacrylamides,
32
 resulting in HD =  3.24 x 10
-6
 cm (HD = 2Dt/L; t = 
time; L = column length, cm). The number of plates for a typical band migrating from the 2D 
separation (see Figure 3.12) was 3.47 x 10
5
, resulting in HTOT = 1.15 x 10
-5
 cm. Therefore, the 
diffusional component to HTOT was calculated to be approximately 28%.  
 For 47 10 s MEKC cycles, which represents the parking time (470 s; time that is 
allocated to performing the MEKC separations) and a total separation time of 3,300 s, the 
percent contribution of diffusional spreading during the parking phases of the separation to 
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HD is roughly 85%. Reductions in the development time for the MEKC cycles can reduce HD 
stemming from the parking phases of the separation, potentially producing higher peak 
capacities. However, due the inherent nature of these proteins being very hydrophobic (i.e. 
membrane proteins), shorter development times for the MEKC dimension is inadvisable 
because the proteins need time to separate in the pseudo-stationary phase. Higher field 
strengths could be utilized but issues of bubble formation from Joule heating could arise.  
In order to sample all components migrating from the 1
st
 dimension to the 2
nd
 
dimension, 47 MEKC cycles were required with each cycle run for 10 s (E = 400V/cm). The 
development time for the full 2D separation was estimated to be ~55 min. Although the 
analysis time is long from a capillary electrophoresis standpoint, this is a significant 
improvement compared to the 24+ h required for a conventional 2D IEF/SDS-PAGE analysis. 
A typical 2D image of the MCF-7 membrane protein separation and the corresponding 3D 
landscape image are shown in Figure 3.13A. The image secured from Figure 3.13A was 
imported into ImageJ for analysis. From the input data to ImageJ, the average size of each 
protein spot for the µ-CE run was determined to be 133 (±7) pixel
2
, which yielded a peak 
capacity for the 2D separation of 1,768 (±9), which was obtained by dividing the total pixel 
area in the image of 235,200 pixel
2
 by the average spot size.  
In order to ensure that the electrophoresis of membrane proteins was working 
properly, we chose 3 known proteins (bovine serum albumin 66 kDa, transferrin 80 kDa, and 
concanavalin A 104 kDa) to separate using the same microfluidic device.  Each protein had a 







Figure 3.13 (A) SDS µCGE/µ-MEKC 2D separation of a MCF-7 membrane protein fraction. 
The protein sample was placed into reservoir A (see Figure 3.7A) and electrokinetically 
injected into the separation channel at 200 V/cm. The 2D SDS µ-CGE × MEKC were 
performed at 350 V/cm and 400 V/cm, respectively. Serial 10 s MEKC cycles were 





dimension. The bottom panel shows a 2D image of the microchip MCF-7 map, while the top 
panel shows a 3D landscape image of the MCF-7 membrane protein map. (B) 2D image of a 
conventional IEF/2D PAGE separation of the MCF-7 membrane protein sample (bottom 
panel) and the corresponding 3D landscape (top panel). Separation conditions are provided in 
the Materials and Methods section. 
 
Figure 3.14 shows the results of the SDS µCGE/µ-MEKC 2D separation of the 3 
known proteins. We utilized conditions described previously in work by Shadpour et al.
24
 The 
2D separation required a total of 71 MEKC cycles with a MEKC cycle run time of 10 s. The 













Figure 3.14 3-D landscape of SDS µCGE/µ-MEKC 2D separation of 3 proteins (bovine 
serum albumin, transferrin, concanavilin A) of known molecular weight. The 2-D SDS µ-
CGE × MEKC were performed at 350 V/cm and 400 V/cm, respectively. Serial 10 s MEKC 







The separation had a peak capacity of 926 (±3.4) and an average plate number of 1.01 
x 10
3
 (±2.3). The data shows that the proteins are well resolved and suggests that there are not 
any issues with the electrophoretic conditions and that any peak broadening is likely a factor 
of the membrane proteins aggregating and not remaining solubilized in the buffer solution 
after the extraction and labeling processes.   
3.4 Conclusion 
 Separations on microfluidic platforms have been attractive for years and are garnering 
more appeal for the analysis of complex biological samples because they can easily lend 
themselves to performance characteristics that rival techniques and instrumentation used on 
the macro-scale, but using shorter operational times without significantly sacrificing 

















these formats, due to their small footprint and lithographic fabrication techniques, will permit 
the development of multi-channel formats that can significantly improve the production rate 
of data. In the present report, we were able to demonstrate the ability to generate peak 
capacities of 1,768 (±9) for a biological membrane protein sample using a 7 cm effective 
separation length in both dimensions. The 2D separation platform is very attractive for 
interfacing to mass spectrometry (MS) for discovery-based applications. The 2D separation 
has band broadening which is likely due to the membrane proteins not being well solubilized. 
In order to overcome the issue of broadening, we can perform a 2D separation on the 
biotinylated MCF-7 membrane proteins that we extracted using the µ-SPE device, which we 
have already shown to be well solubilized and purified from the membrane of the cell and 
other contaminating species (i.e. cytosolic proteins). 
 As stated previously, the goal of this work is to develop an integrated system for the 
analysis of proteins from a top-down perspective. We have already shown the separation of 
intact proteins and now we must discuss how we plan to integrate the extraction and 
separation platforms with the remaining processing steps in the proteomic pipeline for this 
analysis. The next chapter will discuss our approach to how we will select cells and 
biotinylate the cell surface membrane proteins on-chip before moving the membrane proteins 
to the extraction bed to be purified, which we discussed in Chapter 2. After the separation of 
the extracted membrane proteins, we will need to digest the proteins before the MS analysis; 
therefore, we will discuss the fabrication of an on-chip bioreactor for digestion. In Chapter 4, 
we will examine our approach to perform cell selection, biotinylation, and lysis. Additionally, 
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4 Summary and On-going Developments 
4.1 Summary 
 Many researchers have been attempting to integrate various proteomic processing 
steps onto a single microfluidic platform to build an autonomously operating system. 
However, the ultimate goal of integrating several proteomic analysis units into one system for 
building such a multifunctional system has not been realized to-date. As previously discussed 
in Chapter 1, the overall goal of this work is to assemble a fully integrated fluidic system 
using a novel design approach; task-specific modules will be interconnected to a fluidic 
motherboard to provide full process automation for mass-limited samples using circulating 
tumor cells (CTCs) as a demonstrator of the technology. The integrated system will be 
directly interfaced to nanostructure-assisted laser desorption ionization MS (NALDI-MS) to 
provide the ability to identify isolated protein components with little or no operator 
intervention. The design strategy will employ a novel modular format with the system using 4 
modules; (1) cell biotinylation and lysis module; (2) affinity selection module of a particular 
sub-population of the proteome (i.e., those that have been biotinylated); (3) microchip 
electrophoresis module; and (4) solid-phase bioreactor for proteolytic digestion with 
subsequent deposition onto the NALDI plate for reading results via MS analysis. To reduce 
sample complexity and improve the identification efficiency of the various components (i.e., 
proteins) comprising the sample via mass spectrometry (MS), we will select a particular 
organelle for the analysis; in this case the sub-population we propose to focus on is membrane 
proteins from the isolated cells. 
 Multidimensional protein separation is regarded as the workhorse of many proteomic 
studies; therefore, careful attention must be paid toward the development and implementation 
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of multidimensional microelectrophoresis platforms both as an independent proteomic unit 
and as an integral part of a multifunctional system. We demonstrated the ability to generate 
peak capacities around 1,768 (±9) within 1 h for a biological sample of membrane proteins 
from an MCF-7 cell lysate using a microchip separation platform, whose effective separation 
length was 7 cm. While this peak capacity is still far below the total number of protein 
components found in a sample of a cell lysate, the technique remains attractive due to the fact 
that a sample of membrane proteins (representing a complex biological sample) has not been 
separated on a microfluidic platform to date. We were also able to perform a solid-phase 
extraction of biotinylated membrane proteins from MCF-7 cell lysate.  
4.2 On-going Developments and Future Work 
4.2.1 Background 
In Chapters 2 and 3, our efforts were focused on the extraction and separation of 
membrane proteins from CTC surrogates (MCF-7; a breast cancer cell line) and the separation 
of membrane proteins from CTCs, respectively. There is a wealth of literature on the 
development of microfluidic devices (device in this context being units that have only one 





 and proteolytic solid-phase bioreactions.
12-17
 Because complex protein 
samples can require the transfer of sample from one processing step to the next and be a 
source of material loss and/or contamination, it is advantageous to consider the use of a fully 
integrated fluidic system (systems are defined here as units that have various devices 
integrated to them). In these systems, the sample is moved hydrodynamically or 
electrokinetically through the entire processing pipeline without requiring operator 
intervention. This allows for the reduction of analysis time, the ability to improve result 
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reproducibility, and eliminate sample handling by the operator, which can be problematic 
especially for mass-limited samples or those containing proteins that have a tendency to 
adhere with high propensities to surfaces, such as membrane proteins.  
A schematic of the proposed integrated fluidic system we are pursuing is shown in 
Figure 4.1. The system will accommodate all of the necessary processing steps of the analysis 
pipeline using task-specific modules fabricated in thermoplastics with the material selected 
for each module based upon the application needed to produce optimal performance. Micro-
replication from a metal mold master will be utilized to fabricate the modules. 
 
Figure 4.1 Integrated and modular fluidic system for processing a sub-population of a cell 
proteome that is selected via affinity techniques. The fluidic motherboard (MB) is populated 
with 4 modules: (1) Cell retention, biotinylation reactor and lysis module made from PC due 
to its compatibility with the PC membrane; (2) solid-phase affinity module made from 
PMMA due to its high surface load of functional groups when UV-treated; (3) 2D µCE 
module made from PMMA due to its propensity to generate high electrophoretic plate 
numbers; and (4) solid-phase bioreactor for proteolytic digestion of protein components sorted 
via 2D µCE that is also made from PMMA. The modules are interconnected to a PC-based 
motherboard; selected here based on its ability to form membrane values due to its high 
elongation at break threshold.  Other components consist of: HV – high voltage power 
supplies; CD – conductivity detectors; Vac – vacuum; SI – sample inlet; RB – release buffer; 
SV – solenoid valves; LB – lysis buffer; BM – biotin reaction mixture; WB – wash buffer. 
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We will integrate an affinity selection module to the protein processing system to 
select CTCs directly from whole blood with high purity (no-preprocessing required). In order 
to accommodate the capability to process large input volumes to select sufficient numbers of 
CTCs, a series of high aspect ratio fluidic channels (narrow and deep) will be utilized in the 
CTC selection module. While we have already fabricated modules for the extraction of the 
biotinylated cell surface proteins and the separation of membrane proteins from MCF-7 cells, 
we still need to explore how to accomplish the on-chip cell lysis of the CTCs, the label-free 
detection of the proteins, protein digestion, and the mass spectrometry interface. 
4.2.2 Cell Selection Module 
4.2.2.1 Cell Selection, Biotinylation, and Lysis Module Design 
 The design of the cell selection module builds from previous experiences in the 
affinity capture of rare cells from samples such as blood.
18-21
 The previous worked described a 
platform consisting of 51 channels (width = 30 µm; depth = 150 µm) with the walls being 
covalently decorated with anti-EpCAM antibodies. This module could process 1 mL of blood 
in ~40 min with CTC recoveries of 98%.
18
 However, we anticipate the need to process larger 
input volumes to increase the yield of CTCs needed to accommodate the NALDI-MS 
detection/identification phases of the assay. The module design is shown in Figure 4.2. 
For this module, 500 sinusoidal channels will be used so that large input volumes can 
be processed within reasonable timeframes using an optimized linear flow velocity (in terms 
of recovery) of 2.0 mm/s for the EpCAM antigen/antibody pair.
18
 Each channel of the 
selection bed will be 30 µm wide, which is close to the diameter of a CTC and will improve 




Figure 4.2 (A) Schematic of rare cell selection module that can process large input samples 
(~10 mL) with high throughput (<40 min) and a SEM of the molded module, which is made 
from PMMA, is shown in the bottom right. The input/output channels are much larger than 
the cell selection channels, and thus there is a lower pressure drop in these channels; the input 
channel fills before the selection channels. (B&C) Images of cells captured in selection 
channels. 
 
Channels (feed and selection channels) are arranged in a Z-configuration to provide 
the single-channel inlet and outlet. This configuration has been found to minimize bubble 
formation compared to the previous designs that were used during blood filling.
18-21
 A 
volumetric flow rate of 0.45 mL/min will be utilized to generate the linear velocity that is 
needed in each channel (2 mm/s) for CTC recoveries >90%.
18
 
Once the rare cells have been selected, they are essentially “attached” to the channel 
walls of the selection bed. In this state, we will seek to biotinylate the membrane proteins of 
the selected cells. We will covalently attach biotin to the extracellular primary amine groups 
of the membrane proteins, but other functionalities, such as sulfhydryls, can be tagged as well. 
Membrane protein biotinylation provides an anchoring group for the affinity SPE of this sub-
population (as discussed in Chapter 2). Following biotinylation, cells will be washed and then 
lysed with the membrane proteins delipidized and solubilized. Biological membranes are 
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composed of ~50 lipid molecules per protein molecule.
22
 Therefore, the removal of the lipids 
is vital because it can assist in the solubilization of the membrane proteins. The lysis, 
delipidization, and solubilization of the cells will be done using a buffer containing 4% 
CHAPS, Tris, 7M urea, 2M thiourea, and magnesium acetate. Because the SPE of the 
membrane proteins is affinity-based, the buffer will not be carried downstream and will not 
interfere with subsequent processing steps. 
4.2.3 Detection of Proteins Employing Contact Conductivity Detection 
4.2.3.1 Electrochemical Detection (ECD) 
 The readout strategy that is most commonly used for detection methods in 
microfluidic devices is laser-induced fluorescence (LIF) due to the fact that it provides superb 
sensitivity with detection limits approaching the single-molecule level.
23-26
 Regrettably, most 
LIF systems do not lend themselves to developing miniaturized systems with the detector 
components often times requiring much larger footprints compared to those of microfluidic 
devices and also, in most cases the proteins are themselves not fluorescent. As such, 
fluorescent dyes must be appended to the proteins to make them detectable. There have been 
attempts to fabricate miniaturized LIF detectors with integrated capabilities;
27,28
 however, LIF 
requires analytes that either show intrinsic fluorescence or can be readily associated with 
(either covalently or non-covalently) labeling chromophores as noted above; this can 
complicate sample processing. 
 Another strategy that has shown promise in microfluidic applications is the use of 
electrochemical detection (ECD), such as amperometric or potentiometric detection 
systems.
29-39
 Some of the features that make ECD attractive are the simple instrumentation 
that is needed to perform the detection and the favorable sensitivity and limits of detection it 
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offers. However, the target analyte must be intrinsically electroactive or have an electroactive 
species appended to it in order to carry out detection with amperometric or potentiometric 
methods. Conductivity detection can also be considered an electrochemical technique as well. 
It has the ability to detect any analyte irrespective of whether it contains an electroactive 
species or not. The only requirement is that the migrating analyte zones possess a conductivity 
that is different from that of the carrier electrolyte. An additional advantage of conductivity is 
that the performance improves with reduced detection volumes, making it an appealing 
detector for microelectrophoretic separations. There have been reports of detection limits ~10
-
7 





 from our group have demonstrated the use of a simple, 
bipolar-pulse, contact conductivity detector that was integrated directly into a PMMA 
microfluidic device performing electrophoresis for the detection of various mono- or 
polyanionic molecules (i.e., amino acids, peptides, proteins or oligonucleotides) was 
achieved. In this format, voltage pulses of equal amplitude and duration but opposite polarity 
were applied to the conductivity electrodes with the current passing between the electrodes 
measured at the end of the second pulse. The Faradaic reactions that occur at the electrodes 
could be minimized because the pulse frequency was appropriately chosen with respect to the 
cell constant (the time to charge the double layer) and the electrical double layer does not 
have sufficient time to form. The layout of the PMMA device employed for the studies is 
shown in Figure 4.3.  
Several different electrophoresis formats such as MEKC (proteins), free-solution zone 
electrophoresis (FSE) (amino acids and peptides), and reverse-phase ion-pair open channel 
capillary electrochromatography (RP-IPOCCEC) (oligonucleotides) were utilized to separate 
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Figure 4.3 (A) Topographical layout of an assembled microfluidic device with an integrated 
conductivity detector. Injection channel length was 1.0 cm; separation channel was 4.0 cm 
(Leff = 3.0 cm). The separation channel was 15 µm wide and 85 µm deep. The solution 
reservoirs are: (1) sample reservoir; (2) electrolyte reservoir; (3) waste reservoir; and (4) 
receiving reservoir. (B) Optical micrograph of the assembled device cut near the conductivity 
cell using microtoming. (C) Optical micrograph of the integrated conductivity detector (T-
cell, electrode gap ~20 µm). In this micrograph, the cover plate was not assembled to the 
fluidic device. Working and reference electrodes were 127 µm in diameter and were placed 
0.5 cm upstream from the receiving reservoir. (D) SEM of Ni electroform embossing tool 
taken near the receiving electrode. (Reproduced from Galloway, M.; Stryjewski, W.; Henry, 
A.; Ford, S. M.; Llopis, S.; McCarley, R. L.; Soper, S. A. Anal. Chem. 2002, 74, 2407 with 
permission, Copyright 2013). 
 
 Figure 4.4 shows the results from a separation of nine peptides using the PMMA 
microdevice for FSE. The solid line represents the 3
rd
 electrophoretic run and the dotted line 
is the 35
th
 electrophoretic run on the same chip. The electrophoretic conditions were as 
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follows: carrier electrolyte was 100 μM phosphate (pH 5.0) with a 3 s electrokinetic injection 
time and field strength 150 V/cm for the electrophoresis. 
 
Figure 4.4 FSE separation of a peptide mixture (~0.23 μM total peptide concentration) 
consisting of (1) bradykinin, (2) bradykinin fragment 1-5, (3) substance P, (4) [Arg
8
]- 
vasopressin, (5) luteinizing hormone, (6) bombesin, (7) leucine enkephalin, (8) methionine 
enkephalin, and (9) oxytocin in a PMMA device using contact conductivity detection. 
(Reproduced from Galloway, M.; Stryjewski, W.; Henry, A.; Ford, S. M.; Llopis, S.; 
McCarley, R. L.; Soper, S. A. Anal. Chem. 2002, 74, 2407 with permission, Copyright 2013). 
 
The detector was operated at 5.0 kHz with bipolar pulse amplitude of ± 0.5 V. 
Baseline separation of all 9 peptides was achieved in the 3 cm length channel with the 
separation requiring <250 s. The sensing system we will use consists of a pair of electrodes to 
measure the change in the bulk solution conductance created by an electrophoretic band 
migrating through the electrodes. 
We have shown that conductivity sensing can provide a label-less readout modality for 
a variety of materials, including proteins and peptides,
42,43
 but with a limit-of-detection (LOD) 
somewhat inferior to laser-induced fluorescence. To optimize the LOD by increasing the 
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sampling efficiency generated by an electrode pair whose field extends across the entire 
fluidic channel,
42
 we will investigate two approaches, labeled Type I and II (see Figure 4.5). 
We will employ Pt wires placed orthogonal to the output channel in the Type I configuration 
(see Figure 4.5A). This will provide high signal-to-noise ratios, but it also requires the 
placement of the microelectrodes into guide channels by hand using microscopic inspection 















Figure 4.5 Conductivity detectors consisting of Type I (A, B) and Type II (C, D). The Type I 
detector is constructed with Pt wires inserted into guide channels embossed into the fluidic 
structure. The Type II detector use thin-film electrodes lithographically patterned on the cover 
and bottom plates. In both cases, the sampling efficiency is 100%. 
 
Our initial studies have used this conductivity format for rapid system evaluation. The 
Type II configuration is more amenable to simple production through the lithographic 
patterning of thin film metal electrodes and consists of placing electrodes on the top and 
bottom faces of a fluidic channel (see Figure 4.5C). Thin film electrodes can be produced via 
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deposition (sputtering or evaporation) through a shadow mask, lithographically through 
selective etching of a deposited metal layer, or electroplated onto UV modified polymers.
44,45
 
Figure 4.5D schematically shows the assembly process of the Type II detector. The detector 
cell is an integral part of the fluidic module and is replicated during the same embossing step 
used to create the fluid channels by double-sided hot embossing.
46
 In the next step, the bottom 
of the detector cell will be cut through using, for example, laser ablation or high precision 
micromilling. This two-step process can be done in a single step with the use of double-sided 
micro-injection molding, which is capable of making through-holes directly and will be used 
in future efforts.
47
 During module assembly, the detector cell is covered on the top and the 
bottom with polymer films pre-patterned with platinum or other noble metal thin-film 
electrodes. 
Highly sensitive electronic circuitry for conductivity measurements developed by our 
group will be used for this application.
18
 The conductivity measurement circuit has been 
specially designed for applications in micro-environments and uses a gyrator sub-circuit to 
reduce the effects of parasitic capacitance due to wiring and the electrode configuration, 
which otherwise would dominate changes in electrical properties of the solution and degrade 
the LOD of the conductivity measurement. The dimensions of the conductivity detector cell 
and the electrodes will be optimized to provide favorable LODs and sampling efficiencies 
without degrading plate number through zonal dispersion induced by the finite detection 
volume.  
In general, the LOD of conductivity detection is inversely proportional to the detector 
cell constant (K) defined as K = L/A, where L is the distance between the electrodes and A is 
the sensing area of the electrodes. Thus, better LODs are generated by closely spaced 
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electrodes with large surface area. For initial studies, we will use 50 µm electrodes placed 
over 50 µm wide and 50 µm deep microchannels at the sensing area with a gap of 50 μm, but 
these can be reduced to further optimize the LOD for conductivity sensing. Specifically, we 
will also look at various buffer compositions, separation channel lengths and field strengths to 
optimize separation performance (i.e., resolution) and at the same time, reduce development 
time.  The effects of these separation conditions on the conductivity detection limit will be 
evaluated as well.  
4.2.3.2 Heart-cut 2D Separation of Membrane Proteins 
In a heart-cut transfer protocol securing readout results from the first dimension of the 
2D electrophoresis process of the membrane proteins prior to inserting into the second 
dimension would be particularly attractive because it would permit more efficient injection of 
material from the first dimension into the second dimension. For example, using the methods 
described in Chapter 3, <1% of the total electrophoresis band is inevitably injected into the 
second dimension. With heart cutting and online detection in both the first and second 
dimensions, the injection efficiency can conceivably be improved to near 100%.  
Also in Chapter 3, a 1D separation was required to determine when the first peak was 
expected at the end of the first dimension. In those separations, which employed “blinded” 
injection of material from the first dimension into the second dimension, one peak may be 
sampled multiple times into the second dimension, and the transfer efficiency can deteriorate 
as well. Also, prolonged development times are apparent with the blinded injection protocol. 
Figure 4.6 shows the schematic of our approach to heart cutting 2D analysis. In our heart-cut 
protocol, electrode sensors are placed around the end of the first dimension and as a protein 
plug transverses the electrode sensors, the signal generated by the plug above baseline (or 
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background buffer) would, after a preset time, initiate protein movement from the first 
dimension into the second dimension.  
 
Figure 4.6 Schematic of the 2D heart-cut separation layout. Conductivity detectors are placed 
at the end of each separation dimension with preset modes to determine the on and off times. 
 
Therefore, a dual detection process is required. Conductivity sensing would be 
particularly attractive for this due to the simple instrumentation required for the detection 
process and the fact that labeling of the proteins are not required, simplifying sample pre-
processing.  
4.2.4 Proteolytic Digestion of Separated Membrane Proteins 
4.2.4.1 Solid-phase Proteolytic Digestion 
 Solid-phase bioreactors are being utilized more frequently instead of solution-phase 
digestion in-part because in-soluiton digestion can result in autodigestion of the proteolytic 
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enzyme forming peptides, which can complicate identification of the target proteins. While 
this can be minimized using low concentrations of the enzyme, it results in longer reaction 
times (>24 h). Solid-phase bioreactors can eliminate this artifact as well as provide the ability 
to: (i) Reuse the enzyme for subsequent analysis;
48-50
 (ii) enhance the stability and activity of 
the enzyme;
16,51,52
 and (iii) simplify on-line processing in addition to allowing easier 
separation of the reaction products from the enzyme.  
Researchers have adopted various approaches for designing proteolytic reactors 
integrated into microfluidic devices, for example the use of trypsin-coated microparticles 
loaded into microchannels. Our group has generated an interesting approach for performing 
solid-phase bioreactions.
15,53
 The solid-phase bioreactor consists of a channel populated with 
microposts that contain a functional scaffold from which the proteolytic enzyme can be 
covalently linked.
15,53
 We have also shown the use of a solid-phase bioreactor (see Figure 4.7) 
that allowed for continuous deposition onto a MALDI plate, a reaction time of ~24 s, and no 
noticeable loss of enzyme activity throughout the depositions.
15
 
The attractive nature of this approach is that the fluidic module and solid support are 
fabricated in a single step using micro-replication of a thermoplastic.
54
 Following molding of 
the bioreactor and fluidic network, the solid support is exposed to UV radiation to create 
carboxylic acids that can be linked through an amide bond using EDC/NHS coupling 







Figure 4.7 (a) Schematic of the bioreactor. (b) The assembled tryptic digest microfluidic chip 
that includes: PMMA chip and cover slip, inlet and outlet connectors, capillary and stainless 
steel tubing. At the end of the bioreactor are coaxial tubes that were sealed to mix digests with 
a matrix solution and to deposit onto the MALDI target plate (Reproduced from Lee, J.; 
Musyimi, H. K.; Soper, S. A.; Murray, K. K. J Am Soc Mass Spectrom 2008, 19, 964 with 
permission, Copyright 2013, Springer Science and Business Media). 
 
We have shown that by using this arrangement, proteolytic reactions can be carried 
out in ~20 s using either hydrodynamic or electrokinetic pumping.
15,55
 
4.2.4.2 Micropost Arrays for Solid-phase Bioreactor 
 Shortcomings associated with many solid-phase bioreactors are twofold. First, 
diffusional kinetic barriers produced by immobilizing the reagents to the solid support can be 
significant. Reducing the channel dimensions can have a profound impact on the efficiency of 
conversion of the chemical reactant to product during travel through the bioreactor. The 
second shortcoming associated with solid-phase bioreactors is the limited load of chemical 
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reagent to the surface, especially for non-porous materials.  The load level of reagent in the 
bioreactor is determined by the size of the immobilized reagent and the surface area of the 
bioreactor.  For example, assuming an open-bed reactor with a rectangular geometry of 5 x 5 
m, the effective surface area is only (l = 1.0 cm) 2.0 x 10-3 cm2. For a molecule with a cross 
sectional area of 100 Ǻ
2
, this would amount to ~2.0 x 10
11
 molecules attached to the surface 
of the reactor (0.3 pmol).  In order to keep an enzymatic reaction pseudo first order, only 
~0.003 pmol of material could be analyzed.   
To address these issues, researchers have adopted 3D architectures in open 





challenge with these techniques is that many of the reagents required to prepare the hydrogel 
or monolith are incompatible with the material used to fabricate the fluidic chip when 
polymers are the substrate.
57
 Another consideration is the porosities of these materials, which 
can create large pressure drops for material driven through the reactor hydrostatically or 
exclusion effects prohibiting the entrance of large molecules into the reactor bed. Finally, the 
chemical preparation of hydrogels or monoliths adds additional processing time and labor to 
the chip fabrication. 
We will use micropost arrays as the solid-phase bioreactors, which can provide greatly 
increased surface area so that the efficiency of a chemical reaction between the solid and 
fluidized materials can be improved, but do so with minimal amounts of time and labor 
needed to prepare the reactor bed. These reactors consist of microchannels populated with 
microposts generated using hot embossing in a single fabrication step.
15
 Moreover, it has been 
found that micropost arrays can also be utilized to promote mixing or enhance reaction rates.  
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We will use computational fluid dynamics to futher study the flow patterns around the 
posts within the microchannels. We will initiate our studies using posts of 20 m diameter 
and an interpost spacing of 20 m. The channel dimensions for these bioreactors will be 50 
m in depth, 1 mm in width, and 7 mm in length. With these dimensions, the bioreactor 
surface area is approximately 28 mm
2
 with a surface area to volume ratio of 103 mm
-1
. We 
have successfully immobilized trypsin onto PMMA surfaces using microfluidic channels 
populated with microposts. Results for the digestion of cytochrome c using trypsin showed 
that with a residence time of ~20 s, the sequence coverage (ratio of the identified amino acid 
residues to the total number of amino acid residues in the protein) was 98% compared to only 
9% for an open channel reactor of the same size. We will investigate different post geometries 
(e.g. squares, diamonds, circles), post sizes (lateral dimensions) and interpost spacing to 
produce high loads of enzyme and attempt to further reduce the reaction time and efficiency. 
If we desire smaller posts and interpost spacing, we can use UV LiGA to manufacture the 
master for replicating the desired parts using hot embossing.
72
 
We will carefully evaluate the ability of obtaining peptides from a variety of 
membrane proteins using trypsin; however, trypsin cleavage is less frequent for integral 
membrane proteins,
73
 because lysine and arginine residues are not uniformly distributed along 
the protein sequence.
74
 Therefore, trypsin may be used in conjunction with chymotrypsin to 
aid in the sequence coverage and identification of integral membrane proteins. Chymotrypsin, 
although less specific than trypsin, effectively cleaves peptide bonds consisting of amino 
acids with aromatic or large hydrophobic side chains.
75
 This will require the formation of 
mixed-monolayers of enzymes or the sequential patterning of trypsin and chymotrypsin 
reactor beds by masking.  
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4.2.5 NALDI-MS Platform for the Analysis of Mass-limited Samples 
 
 The samples from the digestion module will be continuously depostied from the 
microfluidic system onto a MALDI target for off-line analysis. To improve the mass LOD 
required to further accommodate the microfluidic outputs, we will utilize engineered plates 
comprised of Si nanowires grown via chemical vapor deposition (CVD) techniques onto Si 
substrates (NALDI), which have been shown to improve the LOD by approximately 10-fold 
compared to conventional MALDI.
76-79
 NALDI does not require a matrix, which also results 
in less interference in the low mass range. Also, a NALDI target plate is built on a 
hydrophobic surface that will create narrow lines of aqueous solvent when the chip effluent is 
deposited onto the plate via direct deposition.
80,81
   
 Continous deposition from the fluidic system to the target plate will be utilized for the 
NALDI analysis. The fluidic system will be fit into a stationary mount, a guide channel will 
be embossed into the fluidic motherboard, and used for transporting samples onto the target. 
The NALDI plate will be placed on another mount operated using linear actuators and a 
motion controller interfaced to a computer running LabView. During deposition, the fluidic 
system outlet will be brought into contact with the target for depositing the effluent. The rate 
of target motion will be matched to the (off-line) MS readout rate. After sample deposition, 
the target will be loaded into the MS and spectra acquired. We will also investigate the effects 
of co-deposition of SDS onto MALDI/NALDI plates and its effects on the integrity of the 
MS.  
Recent studies have shown that SDS concentrations ranging from 0.3% to 1.0% (w/v) 
can improve the sequence coverage for proteins analyzed via MALDI-MS,
82-84
 whereas 
concentrations above 1% lead to loss of spectral quality due to excess Na
+
 and also, formation 
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of SDS cluster peaks in the MS. As noted above, for our MEKC dimension of the 2D µCE, 
we will be using SDS concentrations near the CMC (>0.23%), so we will be below the critical 
1% level to maintain MS integrity. In all of the cited work, however, the effects of SDS were 
evaluated for MALDI-MS, in which a matrix was used; the effects of co-deposition of SDS 
with NALDI have not been evaluated. Therefore, we will investigate the effects of SDS 
concentration on the integrity of NALDI. 
4.2.6 Integration of Modules for Membrane Protein Analysis 
The overall goal of this work is to integrate the previously discussed modules to a 
motherboard that possesses a fluidic bus, interconnects and valves for controlling 
reagent/sample flow direction that is driven hydrodynamically through the use of off-chip 
pumps. The proposed integrated system is based on a modular format (see Figure 4.1) and 
consists of four modules. Fluidic modules will be interconnected to the modules using the 
design concept shown in Figure 4.6. An excimer laser will be employed to drill holes of the 
appropriate shape and size into the fluidic motherboard and module. Then, a Tefzel tube will 
be inserted into the laser-drilled holes. 
Exerting pressure on the assembly allows the proper leak-free interconnection (up to 
~600 psi). As can be seen from the micrograph depicted in Figure 4.6, this interconnection 
produces minimal unswept or dead volumes, which is a critical performance metric when 
analyzing mass-limited samples. We will use a combination of electrokinetic and 
hydrodynamic pumping. For example, the cell biotinylation and SPE modules will use 
hydrodynamic pumping with off-chip pumps. 
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Electrokinetic fluid drive will be used for the µ-CE with subsequent deposition onto 
the MALDI plate. We have already discussed the use of COMSOL to investigate the flow 
patterns around microposts for the SPE work (see Chapter 2). COMSOL and/or computational 
fluid dynamics will be employed to study flow patterns around various posted architectures, 
which will include the packing geometry (hexagonal, equilateral or square array), post 
spacing or post diameter.  
 
Figure 4.8 Micrographs on the left show laser drilled holes using an ArF excimer laser into a 
thermoplastic (PC). The schematics on the right show the interconnect technology that will be 
used to provide leak-free connections of modules to the fluidic motherboard. The micrograph 
(bottom right) shows a connection between two polymer pieces with dye filling the fluidic 
via, showing near zero dead volume. 
 
We will also analyze the flow distribution
85,86
 within and between the module and 
motherboard. The transport velocity through posted beds will be optimized with respect to 
balancing the encounter and reaction rates.
87,88
 For electrokinetic driving, we will analyze 
material discontinuities (motherboard/module interfaces and interconnects) to evaluate the 
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effects of material dependent electroosmotic flows (EOFs) that may generate laminar flow 
profiles and consequently, degrade plate numbers for the µ-CE phases of the processing.
89
  
We will employ several on-chip valves (see Figure 4.1, SV1-7) poised on the fluidic 
motherboard. Figure 4.9 shows drawings of the design and operation of these valves, which 
consist of a two-layered structure (fluidic substrate and cover plate) as opposed to three-
layered structures typically employed for PDMS-based membrane values. Valves will be 
actuated with solenoids. Simplicity of fabrication, and the use of a single material 
differentiates these fluid control elements from other on-chip valves, which are typically 













Figure 4.9 Physical operation of the on-chip valve. A – valve in open position, B – valve in 
closed position; 1 – PC chip body; 2 – PC membrane; 3 – inlet; 4 – outlet; 5 – solenoid 
actuated plunger. Half-circle cutouts in the membrane were used for clarity of the pictures.  
 
We have successfully tested these micro-valves with head pressures up to 105 psi with 
no leakage; these valves can take more than an order of magnitude higher pressure load than 
hybrid thermoplastic/elastomeric valves.
95
 The valving membrane (motherboard cover plate) 
used here is PC, with the substrate also made from PC to allow simple thermal fusion bonding 
of these materials. 
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